[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 73 of about 73
1. Inaba H, Pui CH: Glucocorticoid use in acute lymphoblastic leukaemia. Lancet Oncol; 2010 Nov;11(11):1096-106
MedlinePlus Health Information. consumer health - Steroids.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Glucocorticoid use in acute lymphoblastic leukaemia.
  • Glucocorticoids (prednisone and dexamethasone) play an essential part in the treatment of acute lymphoblastic leukaemia (ALL), but their optimum doses and bioequivalence have not been established.
  • In prospective randomised trials, dexamethasone improved control of CNS leukaemia.
  • The selection of the type and dose of glucocorticoid should be based on the risk of relapse, treatment phase, and the chemotherapeutic drugs used concomitantly.

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Ltd. All rights reserved.
  • [Cites] Lancet Oncol. 2009 Feb;10(2):147-56 [19147408.001]
  • [Cites] Blood. 2009 Feb 26;113(9):2014-21 [18978206.001]
  • [Cites] N Engl J Med. 2009 Jun 25;360(26):2730-41 [19553647.001]
  • [Cites] Blood. 2009 Aug 27;114(9):1746-52 [19546477.001]
  • [Cites] Lancet Oncol. 2009 Oct;10(10):957-66 [19747876.001]
  • [Cites] Blood. 2010 Feb 4;115(5):1018-25 [19965632.001]
  • [Cites] Clin Exp Neurol. 1984;20:107-18 [6568935.001]
  • [Cites] Endocrinol Jpn. 1984 Oct;31(5):583-94 [6519032.001]
  • [Cites] Cancer Res. 1985 Dec;45(12 Pt 1):6482-6 [3864532.001]
  • [Cites] J Pharm Sci. 1986 Oct;75(10):973-5 [3795028.001]
  • [Cites] J Clin Oncol. 1987 Feb;5(2):202-7 [3806166.001]
  • [Cites] Cell. 1988 Oct 21;55(2):361-9 [3167984.001]
  • [Cites] Ann Allergy. 1991 May;66(5):414-9 [2035905.001]
  • [Cites] Med Pediatr Oncol. 1991;19(4):269-75 [2056971.001]
  • [Cites] Neurology. 1991 Aug;41(8):1235-9 [1866012.001]
  • [Cites] Blood. 1992 May 1;79(9):2370-7 [1373973.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Jan 18;91(2):752-6 [8290595.001]
  • [Cites] Endocr Rev. 1993 Dec;14(6):659-69 [8119231.001]
  • [Cites] J Neurosci. 1994 Apr;14(4):2047-53 [8198631.001]
  • [Cites] Psychoneuroendocrinology. 1994;19(3):233-55 [7515507.001]
  • [Cites] J Clin Oncol. 1996 Mar;14(3):911-8 [8622039.001]
  • [Cites] Med Pediatr Oncol. 1996 Aug;27(2):114-21 [8649318.001]
  • [Cites] J Clin Oncol. 1996 Aug;14(8):2370-6 [8708730.001]
  • [Cites] Leukemia. 1998 Apr;12(4):619-22 [9557622.001]
  • [Cites] Blood. 1998 Jul 15;92(2):411-5 [9657739.001]
  • [Cites] Cancer. 2000 Apr 15;88(8):1964-9 [10760775.001]
  • [Cites] J Pediatr Hematol Oncol. 2000 May-Jun;22(3):206-13 [10864051.001]
  • [Cites] J Clin Oncol. 2000 Sep 15;18(18):3262-72 [10986059.001]
  • [Cites] J Clin Oncol. 2001 Feb 15;19(4):1040-6 [11181667.001]
  • [Cites] Blood. 2001 Mar 1;97(5):1211-8 [11222362.001]
  • [Cites] J Clin Oncol. 2001 Jun 15;19(12):3066-72 [11408503.001]
  • [Cites] J Clin Endocrinol Metab. 2001 Aug;86(8):3742-5 [11502805.001]
  • [Cites] Leukemia. 2003 Jan;17(1):17-25 [12529655.001]
  • [Cites] Blood. 2003 May 15;101(10):3809-17 [12531809.001]
  • [Cites] Cancer. 2003 Jun 1;97(11):2898-903 [12767105.001]
  • [Cites] N Engl J Med. 2004 Aug 5;351(6):533-42 [15295046.001]
  • [Cites] Science. 2004 Oct 8;306(5694):269-71 [15472075.001]
  • [Cites] Blood. 2004 Nov 1;104(9):2690-6 [15251979.001]
  • [Cites] J Clin Invest. 1973 Jul;52(7):1715-25 [4352461.001]
  • [Cites] J Clin Endocrinol Metab. 1975 Jun;40(6):1073-7 [1133157.001]
  • [Cites] J Clin Endocrinol Metab. 1975 Aug;41(2):290-304 [169279.001]
  • [Cites] Am J Med. 1977 Aug;63(2):200-7 [888843.001]
  • [Cites] Am Fam Physician. 1978 Mar;17(3):198-204 [629197.001]
  • [Cites] J Pediatr. 1978 Aug;93(2):299-303 [671172.001]
  • [Cites] J Cell Physiol. 1979 Feb;98(2):267-78 [422656.001]
  • [Cites] Nature. 1980 Apr 10;284(5756):555-6 [6245367.001]
  • [Cites] Cancer Res. 1981 Oct;41(10):3979-84 [7285007.001]
  • [Cites] J Immunol. 1984 Jul;133(1):273-6 [6427338.001]
  • [Cites] N Engl J Med. 1998 Jul 30;339(5):292-9 [9682041.001]
  • [Cites] J Am Med Assoc. 1950 Dec 16;144(16):1349-53 [14778746.001]
  • [Cites] Pediatr Blood Cancer. 2005 Mar;44(3):220-5 [15514916.001]
  • [Cites] Pharmacol Rep. 2005 Jan-Feb;57(1):47-54 [15849376.001]
  • [Cites] Br J Haematol. 2005 Jun;129(6):734-45 [15952999.001]
  • [Cites] Nature. 2005 Jun 16;435(7044):959-63 [15959515.001]
  • [Cites] J Clin Oncol. 2005 Sep 20;23(27):6489-98 [16170158.001]
  • [Cites] N Engl J Med. 2006 Jan 12;354(2):166-78 [16407512.001]
  • [Cites] Leukemia. 2006 Jul;20(7):1279-87 [16688224.001]
  • [Cites] Blood. 2006 Aug 1;108(3):1045-9 [16574952.001]
  • [Cites] Cancer Cell. 2006 Oct;10(4):331-42 [17010674.001]
  • [Cites] Lancet. 2007 Jan 13;369(9556):123-31 [17223475.001]
  • [Cites] J Clin Oncol. 2007 Apr 20;25(12):1525-31 [17442995.001]
  • [Cites] Blood. 2007 May 1;109(9):3929-35 [17218380.001]
  • [Cites] Arthritis Res Ther. 2007;9 Suppl 1:S7 [17634146.001]
  • [Cites] Eur J Cancer. 2007 Nov;43(17):2532-6 [17702568.001]
  • [Cites] Lancet Oncol. 2008 Mar;9(3):257-68 [18308251.001]
  • [Cites] J Clin Oncol. 2008 Apr 20;26(12):1932-9 [18421047.001]
  • [Cites] J Clin Oncol. 2008 Jun 20;26(18):3038-45 [18565890.001]
  • [Cites] Cancer. 2008 Jul 15;113(2):376-82 [18459178.001]
  • [Cites] Nat Med. 2009 Jan;15(1):50-8 [19098907.001]
  • [Cites] Cancer Cell. 2009 Feb 3;15(2):85-7 [19185842.001]
  • (PMID = 20947430.001).
  • [ISSN] 1474-5488
  • [Journal-full-title] The Lancet. Oncology
  • [ISO-abbreviation] Lancet Oncol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P30 CA021765; United States / NCI NIH HHS / CA / P30 CA021765-34; United States / NCI NIH HHS / CA / CA21765
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Glucocorticoids
  • [Other-IDs] NLM/ NIHMS319128; NLM/ PMC3309707
  •  go-up   go-down


2. Eusni RM, Hamidah Hussin N, Zarina AL, Rahman J: Bone marrow necrosis preceding infantile acute lymphoblastic leukaemia. Malays J Pathol; 2007 Dec;29(2):113-7
MedlinePlus Health Information. consumer health - Bone Marrow Diseases.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bone marrow necrosis preceding infantile acute lymphoblastic leukaemia.
  • We report a case of bone marrow necrosis preceding infantile acute lymphoblastic leukaemia (ALL).
  • Bone marrow necrosis is a rare antemortem event and has been known to be present in many conditions, notably in haematological malignancies like acute lymphoblastic leukaemia.
  • His subsequent marrow 2 weeks later revealed acute lymphoblastic leukaemia (FAB-L1) and immunophenotyping showed precursor B acute lymphoblastic leukaemia-null type.
  • He was started on United Kingdom Acute Lymphoblastic leukaemia (UK ALL) Infantile Leukaemia protocol, however, he defaulted treatment after 3 days.
  • [MeSH-major] Bone Marrow Diseases / complications. Bone Marrow Diseases / pathology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications. Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology

  • Genetic Alliance. consumer health - Bone marrow necrosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19108404.001).
  • [ISSN] 0126-8635
  • [Journal-full-title] The Malaysian journal of pathology
  • [ISO-abbreviation] Malays J Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Malaysia
  •  go-up   go-down


3. Mallol-Mesnard N, Menegaux F, Auvrignon A, Auclerc MF, Bertrand Y, Nelken B, Robert A, Michel G, Margueritte G, Perel Y, Méchinaud F, Bordigoni P, Leverger G, Baruchel A, Hémon D, Clavel J: Vaccination and the risk of childhood acute leukaemia: the ESCALE study (SFCE). Int J Epidemiol; 2007 Feb;36(1):110-6
MedlinePlus Health Information. consumer health - Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Vaccination and the risk of childhood acute leukaemia: the ESCALE study (SFCE).
  • BACKGROUND: In 2002, a poster alerted the French health authorities to the possibility that the risk of childhood leukaemia might be increased by hepatitis B vaccination.
  • Elucidating the role of vaccination in the aetiology of childhood acute leukaemia (AL) was therefore included in the objectives of an ongoing national study.
  • METHODS: The ESCALE study was a French national population-based case-control study conducted in France in 2003 and 2004 in order to investigate the role of infectious, environmental and genetic factors in four childhood neoplastic diseases (leukaemia, lymphoma, neuroblastoma and brain tumour).
  • RESULTS: No association between vaccination and the risk of childhood AL: acute lymphoblastic leukaemia or acute myeloblastic leukaemia was observed.
  • No relationship between the risk of leukaemia and the type of vaccine, number of doses of each vaccine, total number of injections, total number of vaccine doses or number of early vaccinations was evidenced.
  • CONCLUSION: The study did not show any evidence of a role of vaccination in the aetiology of childhood leukaemia.
  • [MeSH-major] Hepatitis B Vaccines / adverse effects. Leukemia / immunology
  • [MeSH-minor] Adolescent. Age Distribution. Case-Control Studies. Child. Child, Preschool. Drug Administration Schedule. Female. France / epidemiology. Humans. Infant. Leukemia, Myeloid, Acute / epidemiology. Leukemia, Myeloid, Acute / immunology. Leukemia, Myeloid, Acute / virology. Male. Precursor Cell Lymphoblastic Leukemia-Lymphoma / epidemiology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / immunology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / virology. Risk Assessment / methods. Sex Distribution. Vaccination / adverse effects

  • MedlinePlus Health Information. consumer health - Childhood Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur J Cancer Prev. 2004 Apr;13(2):97-103 [15100575.001]
  • [Cites] Int J Epidemiol. 2005 Oct;34(5):1100-9 [15951359.001]
  • [Cites] BMJ. 2005 Jun 4;330(7503):1294 [15849205.001]
  • [Cites] Br J Cancer. 1999 Sep;81(1):175-8 [10487630.001]
  • [Cites] Br J Cancer. 1999 Jul;80(9):1483-9 [10424755.001]
  • [Cites] Br J Cancer. 1999 May;80(3-4):585-90 [10408870.001]
  • [Cites] Br J Cancer. 2000 Jan;82(1):234-40 [10638995.001]
  • [Cites] Br J Cancer. 1997;76(9):1241-7 [9365177.001]
  • [Cites] Am J Epidemiol. 1986 Oct;124(4):590-4 [3463201.001]
  • [Cites] Br J Cancer. 2004 Jan 12;90(1):139-45 [14710221.001]
  • [Cites] Arch Pediatr. 2003 May;10(5):403-9 [12878332.001]
  • [Cites] Paediatr Perinat Epidemiol. 2002 Apr;16(2):154-65 [12060313.001]
  • [Cites] Br J Cancer. 2002 Apr 8;86(7):1064-9 [11953850.001]
  • [Cites] Bull World Health Organ. 1999;77(3):224-9 [10212512.001]
  • (PMID = 17227780.001).
  • [ISSN] 0300-5771
  • [Journal-full-title] International journal of epidemiology
  • [ISO-abbreviation] Int J Epidemiol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Hepatitis B Vaccines
  • [Other-IDs] NLM/ HALMS168385; NLM/ PMC2292812
  •  go-up   go-down


Advertisement
4. Pieters R: [Acute lymphoblastic leukaemia in children and adolescents: chance of cure now higher than 80%]. Ned Tijdschr Geneeskd; 2010;154:A1577
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Acute lymphoblastic leukaemia in children and adolescents: chance of cure now higher than 80%].
  • [Transliterated title] Behandeling van acute lymfatische leukemie bij kinderen en adolescenten. Zijn we er bijna?
  • Acute lymphoblastic leukaemia (ALL) is the most prevalent type of cancer in patients under the age of 18 years.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / mortality

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20858304.001).
  • [ISSN] 1876-8784
  • [Journal-full-title] Nederlands tijdschrift voor geneeskunde
  • [ISO-abbreviation] Ned Tijdschr Geneeskd
  • [Language] dut
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Netherlands
  •  go-up   go-down


5. Jarfelt M, Fors H, Lannering B, Bjarnason R: Bone mineral density and bone turnover in young adult survivors of childhood acute lymphoblastic leukaemia. Eur J Endocrinol; 2006 Feb;154(2):303-9
MedlinePlus Health Information. consumer health - Osteoporosis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bone mineral density and bone turnover in young adult survivors of childhood acute lymphoblastic leukaemia.
  • OBJECTIVE: Treatment for childhood leukaemia induces many risk factors for development of decreased bone mineral density (BMD).
  • The aim was to study BMD and markers of bone turnover in a well-defined group of survivors of acute lymphoblastic leukaemia (ALL) who had all reached final height as well as peak bone mass, taking both previous treatment and physical activity into consideration.

  • MedlinePlus Health Information. consumer health - Bone Density.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16452545.001).
  • [ISSN] 0804-4643
  • [Journal-full-title] European journal of endocrinology
  • [ISO-abbreviation] Eur. J. Endocrinol.
  • [Language] ENG
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Collagen Type I; 0 / Peptide Fragments; 0 / Peptides; 0 / Procollagen; 0 / collagen type I trimeric cross-linked peptide; 0 / procollagen type I carboxy terminal peptide; 104982-03-8 / Osteocalcin; EC 3.1.3.1 / Alkaline Phosphatase
  •  go-up   go-down


6. Radhakrishnan A, Sithinamsuwan P, Harvey AS, Flanagan D, Fitt G, Berlangieri S, Jackson GD, Berkovic SF, Scheffer IE: Multifocal epilepsy: the role of palliative resection - intractable frontal and occipital lobe epilepsy secondary to radiotherapy for acute lymphoblastic leukaemia. Epileptic Disord; 2008 Dec;10(4):362-70
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multifocal epilepsy: the role of palliative resection - intractable frontal and occipital lobe epilepsy secondary to radiotherapy for acute lymphoblastic leukaemia.
  • We report an adolescent with intractable frontal and occipital lobe seizures, secondary to complications of treatment for acute lymphoblastic leukaemia as a young child.
  • Careful analysis of the type and impact of focal seizures in the setting of multifocal epilepsy may demonstrate that one seizure type is more deleterious to quality of life and may be amenable to surgery.
  • [MeSH-major] Epilepsies, Partial / etiology. Epilepsies, Partial / surgery. Epilepsy, Frontal Lobe / surgery. Neurosurgical Procedures. Occipital Lobe. Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / complications. Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / radiotherapy. Radiotherapy / adverse effects

  • Genetic Alliance. consumer health - Epilepsy.
  • MedlinePlus Health Information. consumer health - Radiation Therapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19017581.001).
  • [ISSN] 1294-9361
  • [Journal-full-title] Epileptic disorders : international epilepsy journal with videotape
  • [ISO-abbreviation] Epileptic Disord
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


7. Kwan ML, Buffler PA, Wiemels JL, Metayer C, Selvin S, Ducore JM, Block G: Breastfeeding patterns and risk of childhood acute lymphoblastic leukaemia. Br J Cancer; 2005 Aug 8;93(3):379-84
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Breastfeeding patterns and risk of childhood acute lymphoblastic leukaemia.
  • The risk of childhood acute lymphoblastic leukaemia (ALL) was investigated in relation to breastfeeding patterns in the Northern California Childhood Leukaemia Study.
  • Data collected by self-administered and in-person questionnaires from biological mothers of leukaemia cases (age 0-14 years) in the period 1995-2002 were matched to birth certificate controls on date of birth, sex, Hispanic ethnic status, and maternal race.
  • Complimentary feeding characteristics such as type of milk/formula used and age started eating solid foods among breastfed children were not associated with ALL risk.

  • MedlinePlus Health Information. consumer health - Breastfeeding.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Natl Cancer Inst. 1999 Oct 20;91(20):1765-72 [10528028.001]
  • [Cites] Am J Epidemiol. 2004 Dec 1;160(11):1098-107 [15561989.001]
  • [Cites] Int J Cancer. 1999 Dec 10;83(6):712-7 [10597183.001]
  • [Cites] Eur J Cancer. 1999 Dec;35(14):1941-53 [10711237.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Apr 25;97(9):4411-3 [10781030.001]
  • [Cites] Br J Cancer. 2000 Dec;83(11):1559-64 [11076669.001]
  • [Cites] Am J Epidemiol. 2000 Dec 15;152(12):1136-44 [11130619.001]
  • [Cites] Eur J Cancer. 2001 Jan;37(2):234-8 [11166151.001]
  • [Cites] Eur J Clin Nutr. 2001 Mar;55(3):179-85 [11305266.001]
  • [Cites] Br J Cancer. 2001 Nov 30;85(11):1685-94 [11742489.001]
  • [Cites] Br J Cancer. 2002 Apr 8;86(7):1064-9 [11953850.001]
  • [Cites] Br J Cancer. 2002 May 6;86(9):1419-24 [11986774.001]
  • [Cites] Eur J Pediatr. 2002 Apr;161(4):235-7 [12014398.001]
  • [Cites] Am J Public Health. 2002 Jul;92(7):1107-10 [12084691.001]
  • [Cites] Genes Chromosomes Cancer. 2003 May;37(1):36-43 [12661004.001]
  • [Cites] Br J Cancer. 2003 Apr 7;88(7):1035-7 [12671700.001]
  • [Cites] Nat Rev Cancer. 2003 Sep;3(9):639-49 [12951583.001]
  • [Cites] Br J Cancer. 2004 Jan 12;90(1):139-45 [14710221.001]
  • [Cites] Am J Epidemiol. 2004 May 15;159(10):915-21 [15128601.001]
  • [Cites] Cancer Causes Control. 2004 Aug;15(6):559-70 [15280635.001]
  • [Cites] Public Health Rep. 2004 Nov-Dec;119(6):521-35 [15504444.001]
  • [Cites] Leukemia. 1988 Feb;2(2):120-5 [3278171.001]
  • [Cites] Lancet. 1988 Aug 13;2(8607):365-8 [2899774.001]
  • [Cites] Lancet. 1988 Oct 1;2(8614):796-7 [2901637.001]
  • [Cites] Lancet. 1988 Nov 12;2(8620):1136 [2903344.001]
  • [Cites] Lancet. 1988 Dec 10;2(8624):1323-7 [2904050.001]
  • [Cites] J Clin Epidemiol. 1989;42(10):995-1001 [2809658.001]
  • [Cites] Cancer Causes Control. 1992 Sep;3(5):449-56 [1525326.001]
  • [Cites] Int J Epidemiol. 1995 Feb;24(1):27-32 [7797353.001]
  • [Cites] Cancer. 1997 May 15;79(10):2045-51 [9149034.001]
  • [Cites] Br J Cancer. 1997;76(9):1241-7 [9365177.001]
  • [Cites] Int J Cancer Suppl. 1998;11:26-8 [9876473.001]
  • [Cites] Int J Cancer Suppl. 1998;11:29-33 [9876474.001]
  • [Cites] Br J Cancer. 1999 May;80(3-4):585-90 [10408870.001]
  • [Cites] Br J Cancer. 1999 Jul;80(9):1483-9 [10424755.001]
  • [Cites] Br J Cancer. 1999 Aug;80(11):1844-51 [10468308.001]
  • [Cites] Lancet. 1999 Oct 30;354(9189):1499-503 [10551495.001]
  • (PMID = 16052219.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] ENG
  • [Grant] United States / NIEHS NIH HHS / ES / P42 ES004705; United States / NIEHS NIH HHS / ES / R01 ES009137; United States / NCHHSTP CDC HHS / PS / PS42 ES04705; United States / NIEHS NIH HHS / ES / R01 ES09137
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2361562
  •  go-up   go-down


8. Corthals SL, Wynne K, She K, Shimizu H, Curman D, Garbutt K, Reid GS: Differential immune effects mediated by Toll-like receptors stimulation in precursor B-cell acute lymphoblastic leukaemia. Br J Haematol; 2006 Feb;132(4):452-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differential immune effects mediated by Toll-like receptors stimulation in precursor B-cell acute lymphoblastic leukaemia.
  • Acute lymphoblastic leukaemia (ALL) is the most common paediatric malignancy and, although current therapy is widely effective, relapse remains a significant clinical problem for which new treatment strategies are required.
  • The ligation of Toll-like receptors (TLR) on antigen-presenting cells stimulates the generation of strong T-cell helper type 1 (Th1) adaptive immune responses.
  • Although TLR9 ligation has been shown to enhance immunogenicity of a number of leukaemia cell types, there have been few reports of the effects mediated through other TLR.
  • In this study we analysed both the expression of TLR by B-cell precursor ALL cell lines and the effects of individual TLR ligation on the ability of ALL cells to stimulate allogeneic T cells.
  • [MeSH-major] Immunotherapy / methods. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / therapy. Toll-Like Receptors / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16412017.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD40; 0 / Ligands; 0 / Peptidoglycan; 0 / RNA, Messenger; 0 / Toll-Like Receptor 1; 0 / Toll-Like Receptor 2; 0 / Toll-Like Receptor 3; 0 / Toll-Like Receptor 4; 0 / Toll-Like Receptor 5; 0 / Toll-Like Receptor 7; 0 / Toll-Like Receptor 9; 0 / Toll-Like Receptors; 12133JR80S / Guanosine; 82115-62-6 / Interferon-gamma; 9CAS0V66OI / loxoribine
  •  go-up   go-down


9. Eden T: Aetiology of childhood leukaemia. Cancer Treat Rev; 2010 Jun;36(4):286-97
Hazardous Substances Data Bank. FOLIC ACID .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Aetiology of childhood leukaemia.
  • The acute leukaemias account for about 30% of all malignancy seen in childhood across the Western world.
  • A peak incidence of precursor B cell ALL has emerged as socio-economic conditions have improved in countries worldwide.
  • From twin studies and the use of neonatal blood spots it has been possible to back track the first initiating genetic events within critical haemopoietic cells to foetal development in utero for most precursor B cell ALL and some cases of AML.
  • Many environmental factors have been proposed as causative for leukaemia but only ionising irradiation and certain chemicals, e.g. benzene and cytotoxics (alkylators and topoisomerase II inhibitors) have been confirmed and then principally for acute myeloid leukaemia.
  • It appears increasingly likely that delayed, dysregulated responses to 'common' infectious agents play a major part in the conversion of pre-leukaemic clones into overt precursor B cell ALL, the most common form of childhood leukaemia.
  • Constitutional polymorphic alleleic variants in immune response genes (especially the HLA Class II proteins) and cytokines may play a role in determining the type of immune response.
  • There is no single cause for childhood leukaemia and for most individuals a combination of factors appears to be necessary; all involving gene-environment interactions.
  • Here then are clear echoes of the "hygiene hypothesis" regarding the initiation of allergies, autoimmune disease and type I diabetes mellitus in children and young people.
  • [MeSH-major] Leukemia / etiology

  • MedlinePlus Health Information. consumer health - Leukemia.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2010. Published by Elsevier Ltd.
  • (PMID = 20223594.001).
  • [ISSN] 1532-1967
  • [Journal-full-title] Cancer treatment reviews
  • [ISO-abbreviation] Cancer Treat. Rev.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 935E97BOY8 / Folic Acid
  • [Number-of-references] 141
  •  go-up   go-down


10. Szpecht D, Derwich K, Wachowiak J, Konatkowska B, Dworacki G: [Lineage switch - conversion of acute lymphoblastic leukaemia to acute myeloid leukaemia in 4 years old girl]. Med Wieku Rozwoj; 2008 Oct-Dec;12(4 Pt 2):1041-4
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Lineage switch - conversion of acute lymphoblastic leukaemia to acute myeloid leukaemia in 4 years old girl].
  • We report a case of a 4-year-old girl with diagnosed proB acute lymphoblastic leukaemia with co-expression CD33 antigen, treated according to Acute Lymphoblastic Leukaemia Intercontinental - Berlin Frankfurt Münster 2002 (ALL-IC BFM 2002) protocol for standard risk group.
  • The late isolated bone marrow relapse of acute myeloid leukaemia, type 7 was noted in our patient.
  • We recognized this case as a lineage switch acute lymphoblastic leukaemia to acute myeloid leukaemia.
  • In spite of Ida Flag regimen and following Acute Myeloid Leukaemia - Berlin Frankfurt Münster 2004 (AML-BFM 2004) protocol were administered, the clinical and haematological remission was not achieved and the patient died because of disease progression (circulatory and respiratory insufficiency).
  • [MeSH-major] Bone Marrow / pathology. Leukemia, Myeloid, Acute / pathology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • Hazardous Substances Data Bank. DAUNORUBICIN .
  • Hazardous Substances Data Bank. PREDNISONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19531823.001).
  • [Journal-full-title] Medycyna wieku rozwojowego
  • [ISO-abbreviation] Med Wieku Rozwoj
  • [Language] pol
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Poland
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; EC 3.5.1.1 / Asparaginase; VB0R961HZT / Prednisone; ZS7284E0ZP / Daunorubicin; PVDA protocol
  •  go-up   go-down


11. Van Vlierberghe P, Pieters R, Beverloo HB, Meijerink JP: Molecular-genetic insights in paediatric T-cell acute lymphoblastic leukaemia. Br J Haematol; 2008 Oct;143(2):153-68
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular-genetic insights in paediatric T-cell acute lymphoblastic leukaemia.
  • Paediatric T-cell acute lymphoblastic leukaemia (T-ALL) is an aggressive malignancy of thymocytes that accounts for about 15% of ALL cases and for which treatment outcome remains inferior compared to B-lineage acute leukaemias.
  • This review provides an overview of the current knowledge on onco- and tumor suppressor genes in T-ALL and suggests a classification of these genetic defects into type A and type B abnormalities.
  • Type A abnormalities may delineate distinct molecular-cytogenetic T-ALL subgroups, whereas type B abnormalities are found in all major T-ALL subgroups and synergize with these type A mutations during T-cell pathogenesis.
  • [MeSH-major] Genes, Homeobox. Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / genetics. Proto-Oncogenes. Receptors, Antigen, T-Cell / genetics. Signal Transduction / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18691165.001).
  • [ISSN] 1365-2141
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Receptors, Antigen, T-Cell
  • [Number-of-references] 136
  •  go-up   go-down


12. Boag JM, Beesley AH, Firth MJ, Freitas JR, Ford J, Hoffmann K, Cummings AJ, de Klerk NH, Kees UR: Altered glucose metabolism in childhood pre-B acute lymphoblastic leukaemia. Leukemia; 2006 Oct;20(10):1731-7
Hazardous Substances Data Bank. GLUCOSE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Altered glucose metabolism in childhood pre-B acute lymphoblastic leukaemia.
  • To date there has been no definitive research documenting metabolic changes in acute lymphoblastic leukaemia (ALL) cells.
  • [MeSH-major] B-Lymphocytes / metabolism. Glucose / pharmacokinetics. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / metabolism. Precursor Cell Lymphoblastic Leukemia-Lymphoma / metabolism
  • [MeSH-minor] Antigens, CD34 / metabolism. Cell Line, Tumor. Child. Citric Acid Cycle / genetics. Deoxyglucose / pharmacokinetics. Gene Expression Profiling. Gene Expression Regulation, Leukemic. Glucose Transporter Type 1 / genetics. Glucose Transporter Type 1 / metabolism. Glycolysis / genetics. Humans. Lactic Acid / metabolism. RNA, Messenger / metabolism. Up-Regulation

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. 2-DEOXY-D-GLUCOSE .
  • Hazardous Substances Data Bank. LACTIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17041637.001).
  • [ISSN] 0887-6924
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD34; 0 / Glucose Transporter Type 1; 0 / RNA, Messenger; 33X04XA5AT / Lactic Acid; 9G2MP84A8W / Deoxyglucose; IY9XDZ35W2 / Glucose
  •  go-up   go-down


13. Aribi A, Bueso-Ramos C, Estey E, Estrov Z, O'Brien S, Giles F, Faderl S, Thomas D, Kebriaei P, Garcia-Manero G, Pierce S, Cortes J, Kantarjian H, Ravandi F: Biphenotypic acute leukaemia: a case series. Br J Haematol; 2007 Jul;138(2):213-6
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Biphenotypic acute leukaemia: a case series.
  • Biphenotypic acute leukaemia (BAL) is a rare type of leukaemia.
  • Whether patients with BAL should be treated with regimens designed for acute myeloid leukaemia (AML), acute lymphocytic leukaemia (ALL) or both remain unclear.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Leukemia / drug therapy
  • [MeSH-minor] Acute Disease. Adolescent. Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cyclophosphamide / therapeutic use. Cytarabine / therapeutic use. Dexamethasone / therapeutic use. Doxorubicin / therapeutic use. Female. Humans. Immunophenotyping. Leukemia, Myeloid, Acute / drug therapy. Male. Methotrexate / therapeutic use. Middle Aged. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Treatment Outcome. Vincristine / therapeutic use

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Childhood Leukemia.
  • MedlinePlus Health Information. consumer health - Leukemia.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17593028.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 04079A1RDZ / Cytarabine; 5J49Q6B70F / Vincristine; 7S5I7G3JQL / Dexamethasone; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; YL5FZ2Y5U1 / Methotrexate; HCVAD protocol
  •  go-up   go-down


14. Pichler H, Möricke A, Mann G, Teigler-Schlegel A, Niggli F, Nebral K, König M, Inthal A, Krehan D, Dworzak MN, Janousek D, Harbott J, Schrappe M, Gadner H, Strehl S, Haas OA, Panzer-Grümayer R, Attarbaschi A, Berlin-Frankfurt-Münster (BFM) Study Group: Prognostic relevance of dic(9;20)(p11;q13) in childhood B-cell precursor acute lymphoblastic leukaemia treated with Berlin-Frankfurt-Münster (BFM) protocols containing an intensive induction and post-induction consolidation therapy. Br J Haematol; 2010 Apr;149(1):93-100
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic relevance of dic(9;20)(p11;q13) in childhood B-cell precursor acute lymphoblastic leukaemia treated with Berlin-Frankfurt-Münster (BFM) protocols containing an intensive induction and post-induction consolidation therapy.
  • The presence of a dicentric chromosome dic(9;20) has been reported to have an unfavourable prognosis in children with B-cell precursor acute lymphoblastic leukaemia (BCP-ALL).
  • As outcome may be influenced by type and composition of treatment, we analyzed 19 BCP-ALL patients with dic(9;20) who have been treated with ALL-BFM (Berlin-Frankfurt-Münster) protocols that included a 4-drug induction and subsequent consolidation therapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chromosome Aberrations. Chromosomes, Human, Pair 20 / genetics. Chromosomes, Human, Pair 9 / genetics. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / genetics

  • Hazardous Substances Data Bank. DAUNORUBICIN .
  • Hazardous Substances Data Bank. PREDNISONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20067563.001).
  • [ISSN] 1365-2141
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; EC 3.5.1.1 / Asparaginase; VB0R961HZT / Prednisone; ZS7284E0ZP / Daunorubicin; PVDA protocol
  •  go-up   go-down


15. Faure C, Mollié A, Bellec S, Guyot-Goubin A, Clavel J, Hémon D: Geographical variations in the incidence of childhood acute leukaemia in France over the period 1990-2004. Eur J Cancer Prev; 2009 Aug;18(4):267-79
MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Geographical variations in the incidence of childhood acute leukaemia in France over the period 1990-2004.
  • Spatial variations in childhood acute leukaemia (AL) incidence rates were investigated by département, in mainland France, over the period 1990-2004.
  • French National Registry of Childhood Haematological Malignancies data and population counts by type of leukaemia (AL, acute lymphoblastic leukaemia, acute myeloblastic leukaemia), time period (1990-2004, 1990-1994, 1995-1999 and 2000-2004), sex, and age group (0-14, 0-4, 5-9 and 10-14 years of age) were considered.
  • The overall homogeneity of the relative risks of leukaemia was tested, as well as comparison to 1 of each relative risk by the exact Poisson test.
  • The associated maps were slightly heterogeneous; the smoothed SIRs of overall acute lymphoblastic leukaemia of the south-west départements were slightly higher than those of the north-east.
  • The results, however, did not remain stable when investigated by leukaemia type, time period, sex or age group.
  • [MeSH-major] Demography. Leukemia, Myeloid, Acute / epidemiology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / epidemiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19444126.001).
  • [ISSN] 1473-5709
  • [Journal-full-title] European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP)
  • [ISO-abbreviation] Eur. J. Cancer Prev.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


16. Ek T, Mellander L, Hahn-Zoric M, Abrahamsson J: Avidity of tetanus and Hib antibodies after childhood acute lymphoblastic leukaemia - implications for vaccination strategies. Acta Paediatr; 2006 Jun;95(6):701-6
Genetic Alliance. consumer health - Tetanus.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Avidity of tetanus and Hib antibodies after childhood acute lymphoblastic leukaemia - implications for vaccination strategies.
  • AIM: To investigate the possible relationship between serum levels and avidities of antibodies against tetanus toxoid (TT) and Haemophilus influenzae type b (Hib) in children that were vaccinated after treatment for childhood acute lymphoblastic leukaemia (ALL).
  • [MeSH-major] Antibodies, Bacterial / immunology. Antibody Affinity. Haemophilus Vaccines / immunology. Haemophilus influenzae / immunology. Polysaccharides, Bacterial / immunology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / immunology. Tetanus Toxoid / immunology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16754551.001).
  • [ISSN] 0803-5253
  • [Journal-full-title] Acta paediatrica (Oslo, Norway : 1992)
  • [ISO-abbreviation] Acta Paediatr.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Norway
  • [Chemical-registry-number] 0 / Antibodies, Bacterial; 0 / Haemophilus Vaccines; 0 / Haemophilus influenzae type b polysaccharide vaccine; 0 / Polysaccharides, Bacterial; 0 / Tetanus Toxoid
  •  go-up   go-down


17. Le QH, Thomas X, Ecochard R, Iwaz J, Lhéritier V, Michallet M, Fiere D: Initial and late prognostic factors to predict survival in adult acute lymphoblastic leukaemia. Eur J Haematol; 2006 Dec;77(6):471-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Initial and late prognostic factors to predict survival in adult acute lymphoblastic leukaemia.
  • Factors able to predict overall survival in adult patients with acute lymphoblastic leukaemia were assessed according to the period since initiation of the treatment using a Cox proportional hazards model.
  • From 1994 to 2002, 922 patients with acute lymphoblastic leukaemia (excluding French-American-British L3 subtype) were enrolled in a multicentre protocol and followed, with a mean follow up of 58 months.
  • Analyses of the initial (before 100 d) and the late phases were realised after stratification on the type of induction treatment and on the different treatment strategies respectively.
  • Determination of such factors is crucial to adapt postremission therapeutic strategies in acute lymphoblastic leukaemia.
  • [MeSH-major] Precursor Cell Lymphoblastic Leukemia-Lymphoma / diagnosis. Precursor Cell Lymphoblastic Leukemia-Lymphoma / mortality

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16978239.001).
  • [ISSN] 0902-4441
  • [Journal-full-title] European journal of haematology
  • [ISO-abbreviation] Eur. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] Denmark
  •  go-up   go-down


18. Pawelec K, Trzcińska A, Siennicka J, Malinowska I, Litwińska B: [Epstein-Barr infections in children with acute leukaemia. Preliminary report]. Med Wieku Rozwoj; 2008 Jan-Mar;12(1):485-91
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Epstein-Barr infections in children with acute leukaemia. Preliminary report].
  • THE AIM: of this study was to evaluate the effectiveness of laboratory methods used to detect EBV and to monitor EBV infections in children with acute leukaemia.
  • MATERIALS AND METHODS: we conducted the study on 30 children with acute leukaemia.
  • Results of serological investigations indicated the type of EBV infection in our patients.
  • 3. In order to assess the effectiveness of serological and molecular methods in evaluation of EBV infection type in children with acute leukaemia, it is necessary to investigate a larger group of patients and taken at least three times.
  • [MeSH-major] Epstein-Barr Virus Infections / immunology. Herpesvirus 4, Human / isolation & purification. Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18663268.001).
  • [Journal-full-title] Medycyna wieku rozwojowego
  • [ISO-abbreviation] Med Wieku Rozwoj
  • [Language] pol
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Epstein-Barr Virus Nuclear Antigens; 0 / Immunoglobulin G; 0 / Immunoglobulin M
  •  go-up   go-down


19. Furuya ME, González-Martínez F, Vargas MH, Miranda-Novales MG, Bernáldez-Ríos R, Zúñiga-Vázquez G: Guidelines for diagnosing and treating pulmonary infiltrates in children with acute leukaemia: impact of timely decisions. Acta Paediatr; 2008 Jul;97(7):928-34
MedlinePlus Health Information. consumer health - Lung Diseases.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Guidelines for diagnosing and treating pulmonary infiltrates in children with acute leukaemia: impact of timely decisions.
  • AIM: Children with leukaemia are at increased risk of pulmonary complications, often with unspecific clinical data, delayed diagnosis and a high mortality rate.
  • METHODS: Clinical charts of children with acute leukaemia and suspicion of pulmonary involvement were reviewed.
  • RESULTS: Children from group I (n=32) and group II (n=28) did not differ with respect to age (9.3+/-0.5 years old, mean+/-SEM), gender, type, risk and stage of leukaemia, anaemia and neutropenia.
  • CONCLUSIONS: Diagnostic-therapeutic guidelines that incorporate timely decisions constitute a useful algorithm to reduce the length of hospital stay and mortality in children with acute leukaemia and pulmonary infiltrates.
  • [MeSH-major] Leukemia, Myeloid, Acute / complications. Lung Diseases / diagnosis. Lung Diseases / therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18430068.001).
  • [ISSN] 0803-5253
  • [Journal-full-title] Acta paediatrica (Oslo, Norway : 1992)
  • [ISO-abbreviation] Acta Paediatr.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Norway
  •  go-up   go-down


20. Meisel R, Toschke AM, Heiligensetzer C, Dilloo D, Laws HJ, von Kries R: Increased risk for invasive pneumococcal diseases in children with acute lymphoblastic leukaemia. Br J Haematol; 2007 Jun;137(5):457-60
MedlinePlus Health Information. consumer health - Pneumococcal Infections.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Increased risk for invasive pneumococcal diseases in children with acute lymphoblastic leukaemia.
  • There are no current data available on the risk of IPD in children with acute lymphoblastic leukaemia (ALL), the most common type of childhood malignancy.
  • [MeSH-major] Pneumococcal Infections / immunology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / immunology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / microbiology. Streptococcus pneumoniae

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17488489.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


21. Koppen IJ, Hermans FJ, Kaspers GJ: Folate related gene polymorphisms and susceptibility to develop childhood acute lymphoblastic leukaemia. Br J Haematol; 2010 Jan;148(1):3-14
Hazardous Substances Data Bank. FOLIC ACID .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Folate related gene polymorphisms and susceptibility to develop childhood acute lymphoblastic leukaemia.
  • Acute lymphoblastic leukaemia (ALL) is the most common paediatric cancer, accounting for nearly 30% of all paediatric cancers and 80% of childhood leukaemias.
  • This includes an influence of the type of population studied, because there was a difference between Asian and European study results.
  • [MeSH-major] Folic Acid / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics

  • MedlinePlus Health Information. consumer health - Folic Acid.
  • Pharmacogenomics Knowledge Base. meta-databases - Pharmacogenomic Annotation 827858523 for PMID:19775302 [PharmGKB] .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Br J Haematol. 2010 Jun;149(5):797-8; author reply 799-800 [20148884.001]
  • (PMID = 19775302.001).
  • [ISSN] 1365-2141
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article; Meta-Analysis; Review
  • [Publication-country] England
  • [Chemical-registry-number] 935E97BOY8 / Folic Acid; EC 1.5.1.20 / Methylenetetrahydrofolate Reductase (NADPH2)
  • [Number-of-references] 43
  •  go-up   go-down


22. Elmantaser M, Stewart G, Young D, Duncan R, Gibson B, Ahmed SF: Skeletal morbidity in children receiving chemotherapy for acute lymphoblastic leukaemia. Arch Dis Child; 2010 Oct;95(10):805-9
Hazardous Substances Data Bank. PREDNISOLONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Skeletal morbidity in children receiving chemotherapy for acute lymphoblastic leukaemia.
  • BACKGROUND: Children receiving chemotherapy for acute lymphoblastic leukaemia (ALL) may be susceptible to skeletal morbidity.
  • CONCLUSION: The occurrence of skeletal morbidity in ALL children may be influenced by age and the type of glucocorticoids.
  • [MeSH-major] Bone Diseases / etiology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy

  • MedlinePlus Health Information. consumer health - Bone Diseases.
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20576660.001).
  • [ISSN] 1468-2044
  • [Journal-full-title] Archives of disease in childhood
  • [ISO-abbreviation] Arch. Dis. Child.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Glucocorticoids; 7S5I7G3JQL / Dexamethasone; 9PHQ9Y1OLM / Prednisolone
  •  go-up   go-down


23. Pogorzala M, Styczynski J, Kurylak A, Debski R, Wojtkiewicz M, Wysocki M: Health-related quality of life among paediatric survivors of primary brain tumours and acute leukaemia. Qual Life Res; 2010 Mar;19(2):191-8
MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Health-related quality of life among paediatric survivors of primary brain tumours and acute leukaemia.
  • PURPOSE: Comparative assessment of the HRQL of paediatric survivors of brain tumours (BT) and of acute leukaemia against a population of their healthy peers.
  • METHODS: The study consisted of patients who had completed treatment for BT (n=36) or acute leukaemia (n=35) and were aged between 8 and 19.
  • The influence of selected factors (sex, age, time from the end of treatment and type of treatment) on the HRQL result was analysed.
  • RESULTS: In all the aspects analysed (total, physical, psychosocial, emotional, social and school functioning), the HRQL of BT and leukaemia survivors was significantly lower in comparison to their healthy peers.
  • The HRQL of patients after BT treatment was also significantly lower than that of the survivors of leukaemia.
  • [MeSH-major] Central Nervous System Neoplasms / psychology. Leukemia, Myeloid, Acute / psychology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / psychology. Quality of Life / psychology. Sickness Impact Profile. Survivors / psychology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © Springer Science+Business Media B.V. 2010
  • (PMID = 20077142.001).
  • [ISSN] 1573-2649
  • [Journal-full-title] Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation
  • [ISO-abbreviation] Qual Life Res
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


24. Matsuda R, Nikaido Y, Yamada T, Mishima H, Tamaki R: [High-dose radiation-induced meningioma following prophylactic cranial irradiation for acute lymphoblastic leukaemia]. No Shinkei Geka; 2005 Mar;33(3):277-80
Genetic Alliance. consumer health - Radiation induced meningioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [High-dose radiation-induced meningioma following prophylactic cranial irradiation for acute lymphoblastic leukaemia].
  • A 12 year-old girl was treated with prophylatic cranial irradiation for acute lymphoblastic leukaemia (ALL).
  • After surgery, this patient presented meningiomas which histologically, were of the meningothelial type.
  • [MeSH-major] Cranial Irradiation / adverse effects. Meningeal Neoplasms / etiology. Meningioma / etiology. Neoplasms, Second Primary / etiology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / radiotherapy

  • Genetic Alliance. consumer health - Meningioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15773318.001).
  • [ISSN] 0301-2603
  • [Journal-full-title] No shinkei geka. Neurological surgery
  • [ISO-abbreviation] No Shinkei Geka
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 11
  •  go-up   go-down


25. Fakhoury M, de Beaumais T, Médard Y, Jacqz-Aigrain E, Suivi Thérapeutique Pharmacologique de la Société Française de Pharmacologie et de Thérapeutique: [Therapeutic drug monitoring of 6-thioguanine nucleotides in paediatric acute lymphoblastic leukaemia: interest and limits]. Therapie; 2010 May-Jun;65(3):187-93
Hazardous Substances Data Bank. MERCAPTOPURINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Therapeutic drug monitoring of 6-thioguanine nucleotides in paediatric acute lymphoblastic leukaemia: interest and limits].
  • [Transliterated title] Suivi thérapeutique pharmacologique des 6-thioguanine nucléotides dans les leucémies aigues lymphoblastiques de l'enfant: intérêt et limites.
  • 6-mercaptopurine, a key drug for the treatment of acute lymphoblastic leukaemia in children, is a prodrug metabolized into 6-thioguanine (6-TGN) which are the active compounds and into methylated metabolites, primary by thiopurine S-methyltransferase enzyme (TPMT).
  • This enzyme displays important inter subject variability linked to a genetic polymorphism: when treated with standard doses of thiopurine, TPMT-deficient and heterozygous patients are at great risk for developing severe and potentially life-threatening toxicity (hematopoietic, hepatic, mucositis...) but show a better survival rate while patients with high TPMT activity (wild type) present lower peripheral red blood cells 6-TGN concentrations and a higher risk of leukemia relapse.
  • [MeSH-major] 6-Mercaptopurine / therapeutic use. Antimetabolites, Antineoplastic / therapeutic use. Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Thioguanine / therapeutic use

  • Hazardous Substances Data Bank. THIOGUANINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2010 Société Française de Pharmacologie et de Thérapeutique.
  • (PMID = 20699069.001).
  • [ISSN] 0040-5957
  • [Journal-full-title] Thérapie
  • [ISO-abbreviation] Therapie
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; E7WED276I5 / 6-Mercaptopurine; EC 2.1.1.- / Methyltransferases; EC 2.1.1.67 / thiopurine methyltransferase; FTK8U1GZNX / Thioguanine
  •  go-up   go-down


26. Li YN, Zou DH, Gu M, Zhao YZ, Qi JY, Mi YC, Wang JX, Qiu LG: [Cytogenetic and prognostic analysis in adult patients with Philadelphia chromosome-positive and bcr-abl positive acute lymphoblastic leukaemia]. Zhonghua Xue Ye Xue Za Zhi; 2009 May;30(5):298-302

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Cytogenetic and prognostic analysis in adult patients with Philadelphia chromosome-positive and bcr-abl positive acute lymphoblastic leukaemia].
  • OBJECTIVE: To analyze the characteristics of cytogenetic aberration of adults with Philadelphia chromosome-positive (Ph+) and/or bcr-abl positive (bcr-abl+) acute lymphoblastic leukaemia (ALL), and investigate its influence on patients' outcomes.
  • The type, distribution and frequency of chromosome aberration were summarized, and compared among different subgroups. RESULTS:.
  • [MeSH-major] Fusion Proteins, bcr-abl / genetics. Philadelphia Chromosome. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19799123.001).
  • [ISSN] 0253-2727
  • [Journal-full-title] Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
  • [ISO-abbreviation] Zhonghua Xue Ye Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] EC 2.7.10.2 / Fusion Proteins, bcr-abl
  •  go-up   go-down


27. Zeller B, Gustafsson G, Forestier E, Abrahamsson J, Clausen N, Heldrup J, Hovi L, Jonmundsson G, Lie SO, Glomstein A, Hasle H, Nordic Society of Paediatric Haematology and Oncology (NOPHO): Acute leukaemia in children with Down syndrome: a population-based Nordic study. Br J Haematol; 2005 Mar;128(6):797-804
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acute leukaemia in children with Down syndrome: a population-based Nordic study.
  • To determine the epidemiology and outcome of children with Down syndrome (DS) diagnosed with acute leukaemia in the Nordic countries, data registered in the Nordic Society of Paediatric Haematology and Oncology (NOPHO) population-based leukaemia registry were analysed.
  • Of 3494 children with acute leukaemia diagnosed between July 1984 and December 2001, 136 patients (3.9%) with DS were identified.
  • 2.1% of the children with acute lymphoid leukaemia (ALL) and 14.0% of the children with acute myeloid leukaemia (AML) had DS.
  • None of the DS patients had T cell leukaemia.
  • DS patients with AML had significantly lower platelet and white blood cell counts and two-thirds were type M7 as according to the French-American-British classification.
  • [MeSH-major] Down Syndrome / complications. Leukemia, Myeloid / complications. Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications
  • [MeSH-minor] Acute Disease. Age Distribution. Child. Child, Preschool. Disease-Free Survival. Female. Humans. Infant. Infant, Newborn. Male. Norway / epidemiology

  • Genetic Alliance. consumer health - Down Syndrome.
  • MedlinePlus Health Information. consumer health - Down Syndrome.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15755283.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


28. Ramanujachar R, Richards S, Hann I, Webb D: Adolescents with acute lymphoblastic leukaemia: emerging from the shadow of paediatric and adult treatment protocols. Pediatr Blood Cancer; 2006 Nov;47(6):748-56

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adolescents with acute lymphoblastic leukaemia: emerging from the shadow of paediatric and adult treatment protocols.
  • Adolescents and young adults (AYA) with acute lymphoblastic leukaemia (ALL) constitute a distinct population from children and older adults.
  • A systematic review of all published clinical trials, which provide data on treatment and outcome of adolescents with ALL, has been summarised in an effort to determine whether they should be treated on paediatric or adult type protocols.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2006 Wiley-Liss, Inc.
  • (PMID = 16470520.001).
  • [ISSN] 1545-5009
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 51
  •  go-up   go-down


29. Abadie C, Bernard F, Netchine I, Sanlaville D, Roque A, Rossignol S, Coupier I: Acute lymphocytic leukaemia in a child with Beckwith-Wiedemann syndrome harbouring a CDKN1C mutation. Eur J Med Genet; 2010 Nov-Dec;53(6):400-3
Genetic Alliance. consumer health - Beckwith-Wiedemann Syndrome.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acute lymphocytic leukaemia in a child with Beckwith-Wiedemann syndrome harbouring a CDKN1C mutation.
  • We report the case of a 10-year-old patient diagnosed with BWS, harbouring a CDKN1C (p57(KIP2)) mutation, who developed a T-type acute lymphoblastic leukaemia.
  • To our knowledge it is the first report of an acute lymphoblastic leukaemia of T-type in a child with BWS.
  • We discuss the possibility of a link between BWS and leukaemia via one of the few known negative regulator of hematopoiesis, the transforming growth factor beta pathway, depending upon the up-regulation of CDKN1C.
  • [MeSH-major] Beckwith-Wiedemann Syndrome / genetics. Cyclin-Dependent Kinase Inhibitor p57 / genetics. Mutation. Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / genetics

  • Genetic Alliance. consumer health - CHILD Syndrome.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Masson SAS. All rights reserved.
  • (PMID = 20826236.001).
  • [ISSN] 1878-0849
  • [Journal-full-title] European journal of medical genetics
  • [ISO-abbreviation] Eur J Med Genet
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / CDKN1C protein, human; 0 / Cyclin-Dependent Kinase Inhibitor p57
  •  go-up   go-down


30. Garnache-Ottou F, Feuillard J, Ferrand C, Biichle S, Trimoreau F, Seilles E, Salaun V, Garand R, Lepelley P, Maynadié M, Kuhlein E, Deconinck E, Daliphard S, Chaperot L, Beseggio L, Foisseaud V, Macintyre E, Bene MC, Saas P, Jacob MC, GOELAMS and GEIL study: Extended diagnostic criteria for plasmacytoid dendritic cell leukaemia. Br J Haematol; 2009 Jun;145(5):624-36
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extended diagnostic criteria for plasmacytoid dendritic cell leukaemia.
  • The diagnosis of plasmacytoid dendritic cell leukaemia (pDCL) is based on the immunophenotypic profile: CD4(+) CD56(+) lineage(neg) CD45RA(+)/RO(neg) CD11c(neg) CD116(low) CD123(+) CD34(neg) CD36(+) HLA-DR(+).
  • Expression of markers previously found in normal pDC was analysed in 16 pDCL, four pDCL presenting an atypical phenotype (apDCL) and 113 non-pDC - lymphoid or myeloid - acute leukaemia.
  • BDCA-2 was expressed on 12/16 pDCL and on 2/4 apDCL, but was never detected in the 113 non-pDC acute leukaemia cases.
  • BDCA-4 expression was found on 13/16 pDCL, but also in 12% of non-pDC acute leukaemia.
  • High levels of LILRA4 and TCL1A transcripts distinguished pDCL and apDCL from all other acute leukaemia (except B-cell acute lymphoblastic leukaemia for TCL1A).
  • Atypical pDCL can be also identified this way and non-pDC acute leukaemia excluded: this scoring strategy is useful for diagnosing pDCL and apDCL.
  • [MeSH-major] Algorithms. Dendritic Cells / immunology. Leukemia / classification
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Biomarkers / analysis. Child. Female. Flow Cytometry / methods. Humans. Interleukin-3 Receptor alpha Subunit / analysis. Lectins, C-Type / analysis. Leukemia, Myeloid, Acute / immunology. Male. Membrane Glycoproteins / analysis. Middle Aged. Precursor Cell Lymphoblastic Leukemia-Lymphoma / immunology. Proto-Oncogene Proteins / analysis. Receptors, Immunologic / analysis. Reverse Transcriptase Polymerase Chain Reaction / methods. Statistics, Nonparametric

  • MedlinePlus Health Information. consumer health - Childhood Leukemia.
  • MedlinePlus Health Information. consumer health - Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19388928.001).
  • [ISSN] 1365-2141
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers; 0 / CLEC4C protein, human; 0 / Interleukin-3 Receptor alpha Subunit; 0 / LILRA4 protein, human; 0 / Lectins, C-Type; 0 / Membrane Glycoproteins; 0 / Proto-Oncogene Proteins; 0 / Receptors, Immunologic; 0 / TCL1A protein, human
  •  go-up   go-down


31. Al-Tonbary Y, Mansour AK, Ghazy H, Elghannam DM, Abd-Elghaffar HA: Prognostic significance of foetal-like tyrosine kinase 3 mutation in Egyptian children with acute leukaemia. Int J Lab Hematol; 2009 Jun;31(3):320-6
MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic significance of foetal-like tyrosine kinase 3 mutation in Egyptian children with acute leukaemia.
  • In children with acute myelogenous leukaemia (AML), internal tandem duplication of the Flt3 gene (Flt3/ITD) was previously reported and correlated to poor prognosis.
  • Limited data are available about childhood acute lymphoblastic leukaemia (ALL).
  • We analysed bone marrow specimens from 55 newly diagnosed acute leukaemia cases including 30 AML and 25 ALL by genomic PCR for the presence of Flt3/ITD and correlated its presence with clinical outcome.
  • Patients with Flt3/ITD appear to be refractory to primary induction therapy, and for those who achieve remission, there is a high rate of relapse and death so there may be an association between this type of mutation and patient outcome.
  • [MeSH-major] Leukemia, Myeloid, Acute / therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy. fms-Like Tyrosine Kinase 3 / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18336585.001).
  • [ISSN] 1751-553X
  • [Journal-full-title] International journal of laboratory hematology
  • [ISO-abbreviation] Int J Lab Hematol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] EC 2.7.10.1 / FLT3 protein, human; EC 2.7.10.1 / fms-Like Tyrosine Kinase 3
  •  go-up   go-down


32. Bacher N, Tiefenthaler M, Sturm S, Stuppner H, Ausserlechner MJ, Kofler R, Konwalinka G: Oxindole alkaloids from Uncaria tomentosa induce apoptosis in proliferating, G0/G1-arrested and bcl-2-expressing acute lymphoblastic leukaemia cells. Br J Haematol; 2006 Mar;132(5):615-22
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Oxindole alkaloids from Uncaria tomentosa induce apoptosis in proliferating, G0/G1-arrested and bcl-2-expressing acute lymphoblastic leukaemia cells.
  • Here, we investigated for the first time the antiproliferative and apoptotic effects of highly purified oxindole alkaloids, namely isopteropodine (A1), pteropodine (A2), isomitraphylline (A3), uncarine F (A4) and mitraphylline (A5) obtained from Uncaria tomentosa, a South American Rubiaceae, on human lymphoblastic leukaemia T cells (CCRF-CEM-C7H2).
  • Four of the five tested alkaloids inhibited proliferation of acute lymphoblastic leukaemia cells.
  • Our results show the strong apoptotic effects of pteropodine and uncarine F on acute leukaemic lymphoblasts and recommend the alkaloids for further studies in xenograft models.
  • [MeSH-major] Alkaloids / therapeutic use. Cat's Claw. Phytotherapy / methods. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy
  • [MeSH-minor] Apoptosis / drug effects. Blotting, Western / methods. Caspase 9. Caspases / analysis. Cell Proliferation / drug effects. Collagen Type XI / analysis. Cyclin-Dependent Kinase Inhibitor p16 / metabolism. G1 Phase. Humans. Indole Alkaloids / therapeutic use. Indoles / therapeutic use. Proto-Oncogene Proteins c-bcl-2 / metabolism. Serpins / metabolism. Spiro Compounds / therapeutic use. T-Lymphocytes / metabolism. Tumor Cells, Cultured. Viral Proteins / metabolism

  • MedlinePlus Health Information. consumer health - Herbal Medicine.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16445836.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Alkaloids; 0 / COL11A2 protein, human; 0 / Collagen Type XI; 0 / Cyclin-Dependent Kinase Inhibitor p16; 0 / Indole Alkaloids; 0 / Indoles; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / Serpins; 0 / Spiro Compounds; 0 / Viral Proteins; 0 / isomitraphylline; 0 / mitraphylline; 0 / uncarine C; 0 / uncarine E; 0 / uncarine F; 96282-35-8 / interleukin-1beta-converting enzyme inhibitor; EC 3.4.22.- / CASP9 protein, human; EC 3.4.22.- / Caspase 9; EC 3.4.22.- / Caspases
  •  go-up   go-down


33. Fakhoury M, Andreu-Gallien J, Mahr A, Medard Y, Azougagh S, Vilmer E, Jacqz-Aigrain E: Should TPMT genotype and activity be used to monitor 6-mercaptopurine treatment in children with acute lymphoblastic leukaemia? J Clin Pharm Ther; 2007 Dec;32(6):633-9
Hazardous Substances Data Bank. MERCAPTOPURINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Should TPMT genotype and activity be used to monitor 6-mercaptopurine treatment in children with acute lymphoblastic leukaemia?
  • METHODS: We determined the genotypic status and TMPT activity, at diagnosis and after 6 months of maintenance therapy, of 118 children with acute lymphoblastic leukaemia (ALL).
  • RESULTS AND DISCUSSION: Eighty-nine per cent of the children had a homozygous wild-type genotype (group 1), 11% had one or two mutant allele(s) (group 2).
  • [MeSH-major] 6-Mercaptopurine / therapeutic use. Antimetabolites, Antineoplastic / therapeutic use. Methyltransferases / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18021342.001).
  • [ISSN] 0269-4727
  • [Journal-full-title] Journal of clinical pharmacy and therapeutics
  • [ISO-abbreviation] J Clin Pharm Ther
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; E7WED276I5 / 6-Mercaptopurine; EC 2.1.1.- / Methyltransferases; EC 2.1.1.67 / thiopurine methyltransferase
  •  go-up   go-down


34. Rimando MG, Chua MN, Yuson Ed, de Castro-Bernas G, Okamoto T: Prevalence of GSTT1, GSTM1 and NQO1 (609C>T) in Filipino children with ALL (acute lymphoblastic leukaemia). Biosci Rep; 2008 Jun;28(3):117-24
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prevalence of GSTT1, GSTM1 and NQO1 (609C>T) in Filipino children with ALL (acute lymphoblastic leukaemia).
  • In the present paper, we examined the incidence of polymorphic genes involved with the detoxification of exogenous chemicals, including carcinogens, namely GSTT1 (glutathione transferase theta1), GSTM1 (glutathione transferase micro1) and NQO1 (NAD(P)H:quinone oxidoreductase 1) in 60 Filipino paediatric patients with ALL (acute lymphoblastic leukaemia).
  • Screening for NQO1 (609C>T) mutant alleles showed a high incidence of the NQO1 C/C genotype (NQO1 homozygous wild-type allele genotype) in 60.0% of ALL cases and was significantly higher than in the control group (23.3%) (P<0.01).
  • These GSTM1 null and NQO1 wild-type genotypes are independently associated with the risk of ALL in Filipino patients.
  • When these two genotypes, GSTM1 null and NQO1 C/C, were combined, the hazard rate for childhood leukaemia was significantly increased (P<0.001).
  • [MeSH-major] Glutathione Transferase / genetics. NAD(P)H Dehydrogenase (Quinone) / genetics. Neoplasm Proteins / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18444911.001).
  • [ISSN] 1573-4935
  • [Journal-full-title] Bioscience reports
  • [ISO-abbreviation] Biosci. Rep.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Neoplasm Proteins; EC 1.6.5.2 / NAD(P)H Dehydrogenase (Quinone); EC 1.6.5.2 / NQO1 protein, human; EC 2.5.1.- / glutathione S-transferase T1; EC 2.5.1.18 / Glutathione Transferase; EC 2.5.1.18 / glutathione S-transferase M1
  •  go-up   go-down


35. Palle J, Frost BM, Forestier E, Gustafsson G, Nygren P, Hellebostad M, Jonsson OG, Kanerva J, Schmiegelow K, Larsson R, Lönnerholm G, Nordic Society for Paediatric Haematology and Oncology: Cellular drug sensitivity in MLL-rearranged childhood acute leukaemia is correlated to partner genes and cell lineage. Br J Haematol; 2005 Apr;129(2):189-98
Hazardous Substances Data Bank. DOXORUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cellular drug sensitivity in MLL-rearranged childhood acute leukaemia is correlated to partner genes and cell lineage.
  • Rearrangements in the 11q23 region, the site of the mixed lineage leukaemia (MLL) gene, are found in both childhood acute myeloid (AML) and lymphoblastic (ALL) leukaemia.
  • In conclusion, the findings indicate that the cellular drug resistance is correlated to both the cell lineage and the type of 11q23 rearrangement.
  • [MeSH-major] DNA-Binding Proteins / genetics. Drug Resistance, Neoplasm / genetics. Gene Rearrangement. Leukemia, Myeloid / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Proto-Oncogenes / genetics. Transcription Factors / genetics
  • [MeSH-minor] Acute Disease. Adolescent. Antineoplastic Agents / pharmacology. Cell Lineage. Child. Child, Preschool. Chromosomes, Human, Pair 11. Chromosomes, Human, Pair 9. Cytarabine / pharmacology. Cytotoxicity Tests, Immunologic. Doxorubicin / pharmacology. Female. Fluorometry. Glucocorticoids / pharmacology. Histone-Lysine N-Methyltransferase. Humans. Infant. Infant, Newborn. Male. Myeloid-Lymphoid Leukemia Protein. Prospective Studies. Statistics, Nonparametric. Translocation, Genetic

  • Hazardous Substances Data Bank. CYTARABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15813846.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / DNA-Binding Proteins; 0 / Glucocorticoids; 0 / MLL protein, human; 0 / Transcription Factors; 04079A1RDZ / Cytarabine; 149025-06-9 / Myeloid-Lymphoid Leukemia Protein; 80168379AG / Doxorubicin; EC 2.1.1.43 / Histone-Lysine N-Methyltransferase
  •  go-up   go-down


36. You Y, Li QB, Chen ZC, Li WM, Xia LH, Zhou H, Zou P: Fludarabine and cytarabine combined chemotherapy followed by transfusion of donor blood stem cells for treating relapse of acute leukaemia after allogeneic haematopoietic stem cell transplantation. Chin Med J (Engl); 2008 Sep 20;121(18):1770-4
Hazardous Substances Data Bank. VIDARABINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fludarabine and cytarabine combined chemotherapy followed by transfusion of donor blood stem cells for treating relapse of acute leukaemia after allogeneic haematopoietic stem cell transplantation.
  • BACKGROUND: Relapse remains an obstacle to successful allogeneic haematopoietic stem cell transplantation (allo-HSCT) for patients with acute leukaemia and no standard treatment is available.
  • We assessed fludarabine and cytarabine with transfusion of donor haematopoietic stem cell in treating the relapse of acute leukaemia after allo-HSCT.
  • METHODS: Seven patients, median age 34 years, with relapse of acute leukaemia after allo-HSCT received combination chemotherapy of fludarabine with cytarabine for 5 days.
  • Five patients suffered from acute myeloid leukaemia (2 refractory) and 2 refractory acute lymphoblastic leukaemia.
  • DNA sequence analysis at day 30 after treatment identified all as full donor chimera type.
  • Graft versus host disease occurred in 2 patients (acute) and 3 (chronic).
  • The other patients died of leukaemia related deaths.
  • CONCLUSIONS: Fludarabine with cytarabine plus the donor haematopoietic stem cell should be considered as an effective therapeutic regimen for relapse of acute leukaemia after allo-HSCT.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hematopoietic Stem Cell Transplantation. Leukemia, Myeloid, Acute / therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. FLUDARABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19080355.001).
  • [ISSN] 0366-6999
  • [Journal-full-title] Chinese medical journal
  • [ISO-abbreviation] Chin. Med. J.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Antineoplastic Agents; 04079A1RDZ / Cytarabine; FA2DM6879K / Vidarabine; P2K93U8740 / fludarabine
  •  go-up   go-down


37. Manda SO, Feltbower RG, Gilthorpe MS: Investigating spatio-temporal similarities in the epidemiology of childhood leukaemia and diabetes. Eur J Epidemiol; 2009;24(12):743-52
MedlinePlus Health Information. consumer health - Diabetes Type 1.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Investigating spatio-temporal similarities in the epidemiology of childhood leukaemia and diabetes.
  • Childhood acute lymphoblastic leukaemia (ALL) and Type 1 diabetes (T1D) share some common epidemiological features, including rising incidence rates and links with an infectious aetiology.
  • [MeSH-major] Demography. Diabetes Mellitus, Type 1 / epidemiology. Epidemiologic Studies. Precursor Cell Lymphoblastic Leukemia-Lymphoma / epidemiology

  • Genetic Alliance. consumer health - Diabetes.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19784553.001).
  • [ISSN] 1573-7284
  • [Journal-full-title] European journal of epidemiology
  • [ISO-abbreviation] Eur. J. Epidemiol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


38. Beesley AH, Firth MJ, Ford J, Weller RE, Freitas JR, Perera KU, Kees UR: Glucocorticoid resistance in T-lineage acute lymphoblastic leukaemia is associated with a proliferative metabolism. Br J Cancer; 2009 Jun 16;100(12):1926-36
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Glucocorticoid resistance in T-lineage acute lymphoblastic leukaemia is associated with a proliferative metabolism.
  • Glucocorticoids (GCs) are among the most important drugs for acute lymphoblastic leukaemia (ALL), yet despite their clinical importance, the exact mechanisms involved in GC cytotoxicity and the development of resistance remain uncertain.
  • The data also provide the first evidence that altered expression of wild-type MLL may contribute to GC-resistant phenotypes.
  • [MeSH-major] Cell Proliferation / drug effects. Dexamethasone / pharmacology. Drug Resistance, Neoplasm. Methylprednisolone / pharmacology. Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / metabolism. Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / pathology. Signal Transduction / drug effects

  • Genetic Alliance. consumer health - Glucocorticoid Resistance.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • Hazardous Substances Data Bank. METHYLPREDNISOLONE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] FASEB J. 2001 Mar;15(3):693-9 [11259387.001]
  • [Cites] J Biol Chem. 2001 Apr 6;276(14):10984-9 [11278393.001]
  • [Cites] Nucleic Acids Res. 2003 Feb 15;31(4):e15 [12582260.001]
  • [Cites] Mol Cancer Ther. 2003 Jul;2(7):671-7 [12883040.001]
  • [Cites] Mol Cell Biol. 2003 Oct;23(20):7315-28 [14517300.001]
  • [Cites] Genes Dev. 2004 Jun 1;18(11):1272-82 [15145826.001]
  • [Cites] N Engl J Med. 2004 Aug 5;351(6):533-42 [15295046.001]
  • [Cites] J Cell Physiol. 1982 Feb;110(2):155-60 [6121820.001]
  • [Cites] Cancer Res. 1986 Feb;46(2):617-22 [2866834.001]
  • [Cites] Exp Cell Res. 1987 Jan;168(1):95-104 [3465537.001]
  • [Cites] Leuk Res. 1987;11(5):489-98 [3472019.001]
  • [Cites] Blood. 1995 Nov 15;86(10):3861-8 [7579354.001]
  • [Cites] Leukemia. 1998 Sep;12(9):1344-8 [9737681.001]
  • [Cites] Cell Death Differ. 1999 Jan;6(1):79-86 [10200551.001]
  • [Cites] Blood. 1999 Aug 15;94(4):1209-17 [10438708.001]
  • [Cites] Science. 1956 Feb 24;123(3191):309-14 [13298683.001]
  • [Cites] Mol Biotechnol. 2005 Jan;29(1):31-8 [15668517.001]
  • [Cites] Cancer Lett. 2005 Feb 10;218(2):141-51 [15670891.001]
  • [Cites] Eur J Cancer. 2005 Jun;41(9):1300-3 [15869873.001]
  • [Cites] Clin Cancer Res. 2005 Aug 15;11(16):6050-6 [16115950.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Oct 25;102(43):15545-50 [16199517.001]
  • [Cites] Cancer Res. 2005 Nov 1;65(21):9712-8 [16266991.001]
  • [Cites] Br J Haematol. 2005 Nov;131(4):447-56 [16281934.001]
  • [Cites] Blood. 2005 Dec 15;106(13):4131-8 [16118324.001]
  • [Cites] Br J Haematol. 2005 Dec;131(5):579-87 [16351633.001]
  • [Cites] Blood. 2006 Jan 15;107(2):769-76 [16189266.001]
  • [Cites] Blood. 2006 Mar 1;107(5):2061-9 [16293608.001]
  • [Cites] Annu Rev Biochem. 2006;75:629-54 [16756505.001]
  • [Cites] Biochimie. 2006 May;88(5):437-48 [16359766.001]
  • [Cites] Blood. 2006 Jul 15;108(2):711-7 [16822902.001]
  • [Cites] Cancer Lett. 2006 Aug 18;240(1):123-34 [16226372.001]
  • [Cites] Clin Cancer Res. 2006 Aug 1;12(15):4553-61 [16899601.001]
  • [Cites] Science. 2006 Sep 29;313(5795):1929-35 [17008526.001]
  • [Cites] J Biol Chem. 2006 Oct 20;281(42):31222-33 [16931516.001]
  • [Cites] Leukemia. 2006 Oct;20(10):1731-7 [17041637.001]
  • [Cites] Cancer Cell. 2006 Oct;10(4):331-42 [17010674.001]
  • [Cites] J Natl Cancer Inst. 2006 Oct 18;98(20):1462-73 [17047195.001]
  • [Cites] Br J Cancer. 2006 Dec 4;95(11):1537-44 [17117183.001]
  • [Cites] Cell Prolif. 2007 Feb;40(1):64-74 [17227296.001]
  • [Cites] FEBS J. 2007 Mar;274(6):1393-418 [17302740.001]
  • [Cites] Br J Haematol. 2007 Apr;137(2):109-16 [17391490.001]
  • [Cites] Blood. 2007 Apr 15;109(8):3462-9 [17148581.001]
  • [Cites] Cancer Biol Ther. 2007 Feb;6(2):278-87 [17224649.001]
  • [Cites] Blood. 2007 May 1;109(9):3929-35 [17218380.001]
  • [Cites] Br J Haematol. 2007 May;137(4):319-28 [17456054.001]
  • [Cites] Blood. 2007 Aug 15;110(4):1271-7 [17456722.001]
  • [Cites] Blood. 2007 Sep 1;110(5):1429-38 [17495134.001]
  • [Cites] Blood. 2007 Sep 15;110(6):2084-91 [17537996.001]
  • [Cites] Br J Haematol. 2008 Mar;140(6):656-64 [18302714.001]
  • [Cites] Leuk Res. 2009 Feb;33(2):321-5 [18789525.001]
  • [Cites] Blood. 2009 Feb 26;113(9):2014-21 [18978206.001]
  • [ErratumIn] Br J Cancer. 2010 Mar 30;102(7):1200
  • (PMID = 19436302.001).
  • [ISSN] 1532-1827
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Glucocorticoids; 7S5I7G3JQL / Dexamethasone; X4W7ZR7023 / Methylprednisolone
  • [Other-IDs] NLM/ PMC2714233
  •  go-up   go-down


39. Bernard F, Bordigoni P, Simeoni MC, Barlogis V, Contet A, Loundou A, Thuret I, Leheup B, Chambost H, Play B, Auquier P, Michel G: Height growth during adolescence and final height after haematopoietic SCT for childhood acute leukaemia: the impact of a conditioning regimen with BU or TBI. Bone Marrow Transplant; 2009 Apr;43(8):637-42
MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Height growth during adolescence and final height after haematopoietic SCT for childhood acute leukaemia: the impact of a conditioning regimen with BU or TBI.
  • We compared the impact of a conditioning regimen with BU (n=16) or fractionated TBI (n=42) on height growth during adolescence and final height (FH), in 58 adults transplanted for acute leukaemia before adolescence (younger than 9 for girls and 11 for boys, and prepubertal).
  • The influence of the conditioning regimen was assessed using multiple linear regression and adjusting for gender, central nervous system irradiation, age and leukaemia status at transplant and type of transplantation.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation / methods. Leukemia, Myeloid, Acute / physiopathology. Leukemia, Myeloid, Acute / therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / physiopathology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy. Transplantation Conditioning / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19011662.001).
  • [ISSN] 1476-5365
  • [Journal-full-title] Bone marrow transplantation
  • [ISO-abbreviation] Bone Marrow Transplant.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


40. Peasland A, Matheson E, Hall A, Irving J: Alternative splicing of hMLH1 in childhood acute lymphoblastic leukaemia and characterisation of the variably expressed Delta9/10 isoform as a dominant negative species. Leuk Res; 2010 Mar;34(3):322-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Alternative splicing of hMLH1 in childhood acute lymphoblastic leukaemia and characterisation of the variably expressed Delta9/10 isoform as a dominant negative species.
  • Mismatch repair (MMR) deficiency is a common feature of acute lymphoblastic leukaemia (ALL) cell lines and in some cases is due to the mutations of hMLH1 which affect mRNA splicing.
  • Aberrant splicing was found in one child with an aggressive leukaemia in which there was a predominant hMLH1Delta6 form and an associated loss of wild-type hMLH1 protein but this was not accompanied by microsatellite instability.
  • [MeSH-major] Adaptor Proteins, Signal Transducing / genetics. Alternative Splicing / genetics. Nuclear Proteins / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2009 Elsevier Ltd. All rights reserved.
  • (PMID = 19767099.001).
  • [ISSN] 1873-5835
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Adaptor Proteins, Signal Transducing; 0 / MLH1 protein, human; 0 / Nuclear Proteins; 0 / Protein Isoforms; 0 / RNA, Messenger
  •  go-up   go-down


41. Urayama KY, Ma X, Buffler PA: Exposure to infections through day-care attendance and risk of childhood leukaemia. Radiat Prot Dosimetry; 2008;132(2):259-66
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Exposure to infections through day-care attendance and risk of childhood leukaemia.
  • There is growing evidence supporting a role for infections in the aetiology of childhood leukaemia.
  • Hypotheses proposed by both Greaves and Kinlen describe childhood leukaemia to be a rare response to one or more common infections acquired through personal contacts.
  • It is well-documented that in developed countries, exposures to common infections occur more frequently in this type of setting.
  • Within the Northern California Childhood Leukaemia Study, the role of social contact has been assessed and a unique 'child-hours' summary measure incorporating information on the number of months attending a day-care, mean hours per week at this day-care and the number of children in the day-care setting was constructed.
  • In this review, the previously reported day-care results have been described, showing that in non-Hispanic White children, children in the highest category of total child-hours of exposure had a reduced risk of acute lymphoblastic leukaemia (ALL), particularly common B-cell precursor ALL (c-ALL), compared with children without such exposures, with evidence of a dose-response effect.

  • MedlinePlus Health Information. consumer health - Child Care.
  • MedlinePlus Health Information. consumer health - Leukemia.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] BMJ. 2005 Jun 4;330(7503):1294 [15849205.001]
  • [Cites] Br J Cancer. 1999 Jul;80(9):1483-9 [10424755.001]
  • [Cites] Haematologica. 2006 Feb;91(2):240-3 [16461310.001]
  • [Cites] Nat Rev Cancer. 2006 Mar;6(3):193-203 [16467884.001]
  • [Cites] Environ Health Perspect. 2007 Jan;115(1):146-50 [17366835.001]
  • [Cites] Br J Cancer. 2007 Nov 5;97(9):1315-21 [17923868.001]
  • [Cites] Leukemia. 2008 Jan;22(1):189-93 [17690702.001]
  • [Cites] Br J Cancer. 2000 Jan;82(1):234-40 [10638995.001]
  • [Cites] Br J Cancer. 2000 Dec;83(11):1559-64 [11076669.001]
  • [Cites] Am J Epidemiol. 2000 Dec 15;152(12):1136-44 [11130619.001]
  • [Cites] Br J Cancer. 2002 Apr 8;86(7):1064-9 [11953850.001]
  • [Cites] Br J Cancer. 2002 May 6;86(9):1419-24 [11986774.001]
  • [Cites] Paediatr Perinat Epidemiol. 2002 Apr;16(2):154-65 [12060313.001]
  • [Cites] Am J Epidemiol. 2003 Jan 15;157(2):176-82 [12522025.001]
  • [Cites] Br J Cancer. 2004 Jan 12;90(1):139-45 [14710221.001]
  • [Cites] Am J Epidemiol. 2004 May 15;159(10):915-21 [15128601.001]
  • [Cites] Br J Haematol. 2004 Nov;127(3):243-63 [15491284.001]
  • [Cites] Leukemia. 1988 Feb;2(2):120-5 [3278171.001]
  • [Cites] Lancet. 1988 Dec 10;2(8624):1323-7 [2904050.001]
  • [Cites] Am J Epidemiol. 1990 Jan;131(1):1-5 [2403464.001]
  • [Cites] Pediatrics. 1991 Jan;87(1):62-9 [1984620.001]
  • [Cites] BMJ. 1993 Sep 25;307(6907):774 [8219951.001]
  • [Cites] Pediatrics. 1994 Dec;94(6 Pt 2):987-90 [7971086.001]
  • [Cites] J Epidemiol Community Health. 1994 Dec;48(6):601-2 [7830017.001]
  • [Cites] Epidemiol Rev. 1996;18(1):10-28 [8877328.001]
  • [Cites] Br J Cancer. 1997;76(9):1241-7 [9365177.001]
  • [Cites] Br J Cancer. 1999 May;80(3-4):585-90 [10408870.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Aug;14(8):1928-34 [16103439.001]
  • (PMID = 18940822.001).
  • [ISSN] 0144-8420
  • [Journal-full-title] Radiation protection dosimetry
  • [ISO-abbreviation] Radiat Prot Dosimetry
  • [Language] ENG
  • [Grant] United States / NIEHS NIH HHS / ES / PS42 ES04705; United States / NIEHS NIH HHS / ES / R01 ES09137
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2879097
  •  go-up   go-down


42. McClintock-Treep SA, Horny HP, Sotlar K, Foucar MK, Reichard KK: KIT(D816V+) systemic mastocytosis associated with KIT(D816V+) acute erythroid leukaemia: first case report with molecular evidence for same progenitor cell derivation. J Clin Pathol; 2009 Dec;62(12):1147-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] KIT(D816V+) systemic mastocytosis associated with KIT(D816V+) acute erythroid leukaemia: first case report with molecular evidence for same progenitor cell derivation.
  • A case of systemic mastocytosis associated with a clonal haematological non-mast cell lineage disease (SM-AHNMD), where the associated disease is acute erythroid leukaemia (erythroid/myeloid type), is reported.
  • It is believed that this is the first reported case of systemic mastocytosis with erythroid leukaemia where the KIT(D816V+) mutation was detected in all three cell types.
  • Molecular findings provide evidence for derivation of these seemingly morphologically distinct lesions from the same clonal precursor cell.
  • [MeSH-major] Leukemia, Erythroblastic, Acute / genetics. Mastocytosis, Systemic / genetics. Mutation. Proto-Oncogene Proteins c-kit / genetics

  • Genetic Alliance. consumer health - Mast cell disease.
  • Genetic Alliance. consumer health - Systemic mastocytosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19729359.001).
  • [ISSN] 1472-4146
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] EC 2.7.10.1 / Proto-Oncogene Proteins c-kit
  •  go-up   go-down


43. Athale UH, Siciliano SA, Crowther M, Barr RD, Chan AK: Thromboembolism in children with acute lymphoblastic leukaemia treated on Dana-Farber Cancer Institute protocols: effect of age and risk stratification of disease. Br J Haematol; 2005 Jun;129(6):803-10
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Thromboembolism in children with acute lymphoblastic leukaemia treated on Dana-Farber Cancer Institute protocols: effect of age and risk stratification of disease.
  • Children with acute lymphoblastic leukaemia (ALL) are at increased risk for thromboembolism (TE).
  • Gender, ALL-immunophenotype, steroid-type or ASP dosing schedule did not alter the risk but older age and HR-disease were factors predisposing to TE associated with DFCI-ALL protocols.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Thromboembolism / chemically induced

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. PREDNISONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15953008.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Randomized Controlled Trial
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Glucocorticoids; EC 3.5.1.1 / Asparaginase; VB0R961HZT / Prednisone
  •  go-up   go-down


44. Nelarabine: new drug. T-lymphoblastic leukaemia/lymphoma: more evaluation needed. Prescrire Int; 2009 Feb;18(99):3-5
Genetic Alliance. consumer health - Lymphoblastic lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nelarabine: new drug. T-lymphoblastic leukaemia/lymphoma: more evaluation needed.
  • 1) Acute T-lymphoblastic leukaemia and T-lymphoblastic lymphoma are closely related malignant haemopathies.
  • But this type of non-comparative trial cannot demonstrate whether a specific drug increases survival time compared with existing alternatives;.
  • [MeSH-major] Arabinonucleosides / therapeutic use. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19382393.001).
  • [ISSN] 1167-7422
  • [Journal-full-title] Prescrire international
  • [ISO-abbreviation] Prescrire Int
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Arabinonucleosides
  •  go-up   go-down


45. Mandal C, Srinivasan GV, Chowdhury S, Chandra S, Mandal C, Schauer R, Mandal C: High level of sialate-O-acetyltransferase activity in lymphoblasts of childhood acute lymphoblastic leukaemia (ALL): enzyme characterization and correlation with disease status. Glycoconj J; 2009 Jan;26(1):57-73

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High level of sialate-O-acetyltransferase activity in lymphoblasts of childhood acute lymphoblastic leukaemia (ALL): enzyme characterization and correlation with disease status.
  • Previous studies had established an over-expression of 9-O-acetylated sialoglycoproteins (Neu5,9Ac(2)-GPs) on lymphoblasts of childhood acute lymphoblastic leukaemia (ALL).
  • Sialate-O-acetyltransferase activity increased at the diagnosis of leukaemia, decreased with clinical remission and sharply increased again in relapsed patients as determined by radiometric-assay.
  • This is the first report on sialate-O-acetyltransferase in ALL being one of the few descriptions of an enzyme of this type in human.
  • [MeSH-major] Acetyltransferases / metabolism. Bone Marrow / enzymology. Microsomes / enzymology. Neoplasm Proteins / metabolism. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / enzymology. Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / enzymology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18677580.001).
  • [ISSN] 1573-4986
  • [Journal-full-title] Glycoconjugate journal
  • [ISO-abbreviation] Glycoconj. J.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Neoplasm Proteins; 72-89-9 / Acetyl Coenzyme A; EC 2.3.1.- / Acetyltransferases; EC 2.3.1.- / N-acylneuraminate-9(7)-O-acetyltransferase; F469818O25 / Cytidine Monophosphate; GZP2782OP0 / N-Acetylneuraminic Acid
  •  go-up   go-down


46. Wiernikowski JT, Barr RD, Webber C, Guo CY, Wright M, Atkinson SA: Alendronate for steroid-induced osteopenia in children with acute lymphoblastic leukaemia or non-Hodgkin's lymphoma: results of a pilot study. J Oncol Pharm Pract; 2005 Jun;11(2):51-6
Hazardous Substances Data Bank. CALCIUM, ELEMENTAL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Alendronate for steroid-induced osteopenia in children with acute lymphoblastic leukaemia or non-Hodgkin's lymphoma: results of a pilot study.
  • BACKGROUND/OBJECTIVES: Osteopenia is a significant morbidity in children undergoing therapy for acute lymphoblastic leukaemia (ALL) or non-Hodgkin's lymphoma (NHL).
  • Outcome measures were WB-BMC and LS-BMD; biochemical measures of bone mineral metabolism including plasma osteocalcin, C-terminal telopeptide of type I collagen (CTx), serum calcium, 25-hydroxy-vitamin D (25-OHD), and parathyroid hormone (PTH); as well as assessments of motor function and HRQL.
  • [MeSH-major] Adrenal Cortex Hormones / adverse effects. Alendronate / therapeutic use. Bone Density Conservation Agents / therapeutic use. Bone Diseases, Metabolic / drug therapy. Lymphoma, Non-Hodgkin / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy
  • [MeSH-minor] Absorptiometry, Photon. Administration, Oral. Adolescent. Bone Density / drug effects. Calcium / blood. Calcium Carbonate / administration & dosage. Calcium Carbonate / therapeutic use. Child. Child, Preschool. Collagen / blood. Collagen Type I. Female. Humans. Lumbar Vertebrae / drug effects. Lumbar Vertebrae / metabolism. Male. Osteocalcin / blood. Osteocalcin / drug effects. Parathyroid Hormone / blood. Peptides / blood. Pilot Projects. Quality of Life. Time Factors. Treatment Outcome. Vitamin D / blood

  • Genetic Alliance. consumer health - Lymphoblastic lymphoma.
  • MedlinePlus Health Information. consumer health - Steroids.
  • Hazardous Substances Data Bank. CALCIUM CARBONATE .
  • Hazardous Substances Data Bank. Alendronic acid .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16460605.001).
  • [ISSN] 1078-1552
  • [Journal-full-title] Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners
  • [ISO-abbreviation] J Oncol Pharm Pract
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Adrenal Cortex Hormones; 0 / Bone Density Conservation Agents; 0 / Collagen Type I; 0 / Parathyroid Hormone; 0 / Peptides; 0 / collagen type I trimeric cross-linked peptide; 104982-03-8 / Osteocalcin; 1406-16-2 / Vitamin D; 9007-34-5 / Collagen; H0G9379FGK / Calcium Carbonate; SY7Q814VUP / Calcium; X1J18R4W8P / Alendronate
  •  go-up   go-down


47. Meier M, den Boer ML, Hall AG, Irving JA, Passier M, Minto L, van Wering ER, Janka-Schaub GE, Pieters R: Relation between genetic variants of the ataxia telangiectasia-mutated (ATM) gene, drug resistance, clinical outcome and predisposition to childhood T-lineage acute lymphoblastic leukaemia. Leukemia; 2005 Nov;19(11):1887-95
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Relation between genetic variants of the ataxia telangiectasia-mutated (ATM) gene, drug resistance, clinical outcome and predisposition to childhood T-lineage acute lymphoblastic leukaemia.
  • The T-lineage phenotype in children with acute lymphoblastic leukaemia (ALL) is associated with in vitro drug resistance and a higher relapse-risk compared to a precursor B phenotype.
  • Our study was aimed to investigate whether mutations in the ATM gene occur in childhood T-lineage acute lymphoblastic leukaemia (T-ALL) that are linked to drug resistance and clinical outcome.
  • However, T-ALL patients carrying these five coding alterations presented with a higher white blood cell count at diagnosis (P = 0.05) and show an increased relapse-risk (5-year probability of disease-free survival (pDFS) = 48%) compared to patients with other alterations or wild-type ATM (5-year pDFS = 76%, P = 0.05).
  • [MeSH-major] Cell Cycle Proteins / genetics. DNA-Binding Proteins / genetics. Leukemia-Lymphoma, Adult T-Cell / drug therapy. Leukemia-Lymphoma, Adult T-Cell / genetics. Polymorphism, Single Nucleotide. Protein-Serine-Threonine Kinases / genetics. Tumor Suppressor Proteins / genetics

  • Genetic Alliance. consumer health - Ataxia.
  • Genetic Alliance. consumer health - Ataxia Telangiectasia.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DAUNORUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Leukemia. 2006 Mar;20(3):526-7; author reply 527 [16408093.001]
  • (PMID = 16167060.001).
  • [ISSN] 0887-6924
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Cell Cycle Proteins; 0 / DNA-Binding Proteins; 0 / Tumor Suppressor Proteins; EC 2.7.11.1 / ATM protein, human; EC 2.7.11.1 / Ataxia Telangiectasia Mutated Proteins; EC 2.7.11.1 / Protein-Serine-Threonine Kinases; ZS7284E0ZP / Daunorubicin
  •  go-up   go-down


48. Attarbaschi A, Pisecker M, Inthal A, Mann G, Janousek D, Dworzak M, Pötschger U, Ullmann R, Schrappe M, Gadner H, Haas OA, Panzer-Grümayer R, Strehl S, Austrian Berlin-Frankfurt-Münster (BFM) Study Group: Prognostic relevance of TLX3 (HOX11L2) expression in childhood T-cell acute lymphoblastic leukaemia treated with Berlin-Frankfurt-Münster (BFM) protocols containing early and late re-intensification elements. Br J Haematol; 2010 Jan;148(2):293-300
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic relevance of TLX3 (HOX11L2) expression in childhood T-cell acute lymphoblastic leukaemia treated with Berlin-Frankfurt-Münster (BFM) protocols containing early and late re-intensification elements.
  • TLX3 expression (TLX3+) in childhood T-cell acute lymphoblastic leukaemia (T-ALL) seems to be associated with a poor prognosis when treated with regimens that lack early and/or late re-intensification therapy elements.
  • Because such elements are essential components of the ALL-BFM (Berlin-Frankfurt-Münster) protocols, we evaluated whether TLX3+ T-ALL patients benefit from this type of therapy.
  • Although molecular disease was frequently present after a 4-drug induction therapy, final treatment outcome was excellent indicating that TLX3+ T-ALL cases may benefit from a BFM-type of ALL therapy with early and late re-intensification elements.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Antineoplastic Combined Chemotherapy Protocols. Homeodomain Proteins / metabolism. Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / metabolism

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. DAUNORUBICIN .
  • Hazardous Substances Data Bank. PREDNISONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19821827.001).
  • [ISSN] 1365-2141
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Homeodomain Proteins; 0 / NUP214-ABL1 fusion protein, human; 0 / Oncogene Proteins, Fusion; 0 / TLX3 protein, human; 5J49Q6B70F / Vincristine; EC 3.5.1.1 / Asparaginase; VB0R961HZT / Prednisone; ZS7284E0ZP / Daunorubicin; PVDA protocol
  •  go-up   go-down


49. Uyttebroeck A, Suciu S, Laureys G, Robert A, Pacquement H, Ferster A, Marguerite G, Mazingue F, Renard M, Lutz P, Rialland X, Mechinaud F, Cavé H, Baila L, Bertrand Y, Children's Leukaemia Group (CLG) of the European Organisation for Research and Treatment of Cancer (EORTC): Treatment of childhood T-cell lymphoblastic lymphoma according to the strategy for acute lymphoblastic leukaemia, without radiotherapy: long term results of the EORTC CLG 58881 trial. Eur J Cancer; 2008 Apr;44(6):840-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of childhood T-cell lymphoblastic lymphoma according to the strategy for acute lymphoblastic leukaemia, without radiotherapy: long term results of the EORTC CLG 58881 trial.
  • From June 1989 through to November 1998, 121 children with newly diagnosed T-cell lymphoblastic lymphoma (T-LBL) were included in the EORTC 58881 trial conducted by the Children's Leukaemia Group.
  • An intensive acute lymphoblastic leukaemia type chemotherapy regimen without irradiation leads to a high cure and survival rate in childhood T-LBL without an increased CNS recurrence.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / drug therapy

  • Genetic Alliance. consumer health - Lymphoblastic lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18342502.001).
  • [ISSN] 0959-8049
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / 5U10-CA11488-18; United States / NCI NIH HHS / CA / 5U10-CA11488-19; United States / NCI NIH HHS / CA / 5U10-CA11488-20; United States / NCI NIH HHS / CA / 5U10-CA11488-21; United States / NCI NIH HHS / CA / 5U10-CA11488-22; United States / NCI NIH HHS / CA / 5U10-CA11488-23; United States / NCI NIH HHS / CA / 5U10-CA11488-24; United States / NCI NIH HHS / CA / 5U10-CA11488-25; United States / NCI NIH HHS / CA / 5U10-CA11488-26; United States / NCI NIH HHS / CA / 5U10-CA11488-27; United States / NCI NIH HHS / CA / 5U10-CA11488-28; United States / NCI NIH HHS / CA / 5U10-CA11488-29; United States / NCI NIH HHS / CA / 5U10-CA11488-30; United States / NCI NIH HHS / CA / 5U10-CA11488-31; United States / NCI NIH HHS / CA / 5U10-CA11488-32; United States / NCI NIH HHS / CA / 5U10-CA11488-33; United States / NCI NIH HHS / CA / 5U10-CA11488-34; United States / NCI NIH HHS / CA / 5U10-CA11488-35; United States / NCI NIH HHS / CA / 5U10-CA11488-36
  • [Publication-type] Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Investigator] Philippet P; Otten J; Plouvier E; Béhar C; Boutard P; Millot F; Waterkeyn C; Velde IV; Solbu G
  •  go-up   go-down


50. Childhood Acute Lymphoblastic Leukaemia Collaborative Group (CALLCG): Beneficial and harmful effects of anthracyclines in the treatment of childhood acute lymphoblastic leukaemia: a systematic review and meta-analysis. Br J Haematol; 2009 May;145(3):376-88

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Beneficial and harmful effects of anthracyclines in the treatment of childhood acute lymphoblastic leukaemia: a systematic review and meta-analysis.
  • Anthracyclines are used to treat childhood acute lymphoblastic leukaemia (ALL) but non-randomized studies suggest that cardiotoxicity may be a problem.
  • Results were grouped and combined according to: addition of an anthracycline to standard therapy, type of anthracycline, mode of administration, and the use of a cardioprotectant.
  • The evidence on type of anthracycline, method of administration or use of cardioprotectant was insufficient to be able to rule out important differences.
  • [MeSH-major] Anthracyclines / therapeutic use. Antibiotics, Antineoplastic / therapeutic use. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Semin Oncol. 2006 Jun;33(3 Suppl 8):S8-14 [16781284.001]
  • [Cites] Semin Oncol. 2006 Jun;33(3 Suppl 8):S2-7 [16781283.001]
  • [Cites] Cochrane Database Syst Rev. 2006;(4):CD005008 [17054232.001]
  • [Cites] Eur J Cancer. 2006 Dec;42(18):3191-8 [16987655.001]
  • [Cites] Br J Cancer. 2007 Jan 29;96(2):226-30 [17242696.001]
  • [Cites] Klin Padiatr. 2007 May-Jun;219(3):134-8 [17525906.001]
  • [Cites] J Clin Oncol. 2008 Mar 1;26(7):1106-11 [18309945.001]
  • [Cites] J Clin Oncol. 2001 Jan 1;19(1):191-6 [11134212.001]
  • [Cites] Blood. 2001 Mar 1;97(5):1211-8 [11222362.001]
  • [Cites] J Clin Oncol. 2001 Mar 1;19(5):1444-54 [11230490.001]
  • [Cites] Cancer. 2002 Jan 1;94(1):25-36 [11815957.001]
  • [Cites] J Clin Oncol. 2002 Mar 15;20(6):1677-82 [11896119.001]
  • [Cites] Ann Oncol. 2002 Apr;13(4):503-12 [12056699.001]
  • [Cites] Ann Oncol. 2002 Jun;13(6):819-29 [12123328.001]
  • [Cites] Cancer. 2002 Oct 15;95(8):1767-72 [12365026.001]
  • [Cites] Am J Hematol. 2002 Dec;71(4):241-7 [12447951.001]
  • [Cites] N Engl J Med. 2004 Jul 8;351(2):145-53 [15247354.001]
  • [Cites] Cancer. 1974 Feb;33(2):545-54 [4521474.001]
  • [Cites] Ned Tijdschr Geneeskd. 1975 Sep 20;119(38):1445-51 [1101081.001]
  • [Cites] Cancer. 1976 Mar;37(3):1243-7 [1063049.001]
  • [Cites] Med Pediatr Oncol. 1977;3(3):281-7 [284168.001]
  • [Cites] Am J Pediatr Hematol Oncol. 1989 Summer;11(2):125-33 [2665546.001]
  • [Cites] Br J Haematol. 1991 Jun;78(2):187-96 [2064956.001]
  • [Cites] Cancer. 1993 Nov 15;72(10):3120-30 [8221579.001]
  • [Cites] Mol Aspects Med. 1994;15 Suppl:s207-12 [7752832.001]
  • [Cites] Cochrane Database Syst Rev. 2005;(1):CD003917 [15674919.001]
  • [Cites] Cochrane Database Syst Rev. 2006;(4):CD005006 [17054231.001]
  • (PMID = 19236609.001).
  • [ISSN] 1365-2141
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Grant] United Kingdom / Medical Research Council / / MRC/ MC/ U137686856; United States / NCI NIH HHS / CA / U10 CA029139-22; United Kingdom / Medical Research Council / / ; United Kingdom / Cancer Research UK / /
  • [Publication-type] Journal Article; Meta-Analysis; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anthracyclines; 0 / Antibiotics, Antineoplastic; 0 / Cardiotonic Agents
  • [Number-of-references] 29
  • [Other-IDs] NLM/ NIHMS163765; NLM/ PMC2812732
  • [Investigator] Yetgin S; Obek NY; Masera G; Valsecchi MG; Dacou-Voutetakis; Loening L; Schrappe M; Zimmermann M; Henze G; von Stackelberg A; Gadner H; Mann G; Attarbaschi A; Brandalise SR; Carroll WL; Gaynon P; Boyett JM; Nachman J; Devidas M; Sather HN; Escherich G; Janka G; Gelber RD; Sallan SE; Pieters R; Bierings M; Kamps WA; Otten J; Suciu S; Viana MB; Baruchel A; Auclerc M; Perez C; Solidaro A; Stark B; Steinberg D; Koizumi S; Tsurusawa M; Zintl F; Schiller I; Matsuzaki A; Eden TO; Lilleyman JS; Richards S; Steinherz PG; Steinherz L; Kochupillai V; Bakhshi S; Ortega JJ; Nachman J; Appelbaum FR; Cheng C; Pei D; Pui CH; Kukure P; Nakazawa S; Tsuchida M; Elphinstone T; Evans V; Gettins L; Hicks C; MacKinnon L; Morris P; Richards S; Wade R
  •  go-up   go-down


51. Novotny JR, Müller-Beissenhirtz H, Herget-Rosenthal S, Kribben A, Dührsen U: Grading of symptoms in hyperleukocytic leukaemia: a clinical model for the role of different blast types and promyelocytes in the development of leukostasis syndrome. Eur J Haematol; 2005 Jun;74(6):501-10
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Grading of symptoms in hyperleukocytic leukaemia: a clinical model for the role of different blast types and promyelocytes in the development of leukostasis syndrome.
  • OBJECTIVE: Patients with hyperleukocytic leukaemia were graded according to the severity of symptoms possibly caused by leukostasis to evaluate the effectiveness of therapy and to test the relative contribution of blast type and count of blasts and promyelocytes in the development of leukostasis syndrome.
  • METHODS: Ninety-five patients (59 male, 36 female, median age 52 yr) with hyperleukocytic leukaemia [leukocytes above 50 x 10(9)/L, 48 acute myeloid leukaemia (AML), 31 chronic myeloid leukaemia (CML), 13 acute lymphoblastic leukaemia (ALL), three chronic myelomonocytic leukaemia (CMML)] were grouped according to the presence or absence and severity of neurologic, pulmonary and other symptoms into four categories (no, possible, probable and highly probable leukostasis syndrome).
  • RESULTS: Patients with myeloid leukaemia (AML M1/M2, CML) which scored as highly probable leukostasis showed significantly higher WBC (P = 0.011), lower haemoglobin (P = 0.004), higher peripheral blast counts (P = 0.004) and higher total of peripheral blasts plus promyelocytes (P < 0.001) compared with the lower probability groups.
  • In leukaemia involving the monocytic lineage (AML M4/M5, CMML) no significant differences were found in any of these factors between patients with highly probable leukostasis and the other patients.
  • We further demonstrate that the mechanisms of leukostasis are different in myeloid leukaemia as compared with leukaemia with involvement of the monocytic lineage.
  • [MeSH-major] Blast Crisis / pathology. Leukemia, Myeloid / pathology. Myelodysplastic Syndromes / pathology
  • [MeSH-minor] Adolescent. Adult. Age Factors. Aged. Aged, 80 and over. Cell Lineage. Female. Granulocyte Precursor Cells / pathology. Hemoglobins / analysis. Humans. Leukocyte Count. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Myelodysplastic Syndromes.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15876254.001).
  • [ISSN] 0902-4441
  • [Journal-full-title] European journal of haematology
  • [ISO-abbreviation] Eur. J. Haematol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Hemoglobins
  •  go-up   go-down


52. Karrman K, Kjeldsen E, Lassen C, Isaksson M, Davidsson J, Andersson A, Hasle H, Fioretos T, Johansson B: The t(X;7)(q22;q34) in paediatric T-cell acute lymphoblastic leukaemia results in overexpression of the insulin receptor substrate 4 gene through illegitimate recombination with the T-cell receptor beta locus. Br J Haematol; 2009 Feb;144(4):546-51
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The t(X;7)(q22;q34) in paediatric T-cell acute lymphoblastic leukaemia results in overexpression of the insulin receptor substrate 4 gene through illegitimate recombination with the T-cell receptor beta locus.
  • The t(X;7)(q22;q34), a translocation not previously reported in a neoplastic disorder, was identified and molecularly characterised in a paediatric T-cell acute lymphoblastic leukaemia (T-ALL), subsequently shown also to harbour a deletion of 6q, a STIL/TAL1 fusion and an activating NOTCH1 mutation.
  • The latter region contains only two known genes, namely insulin receptor substrate 4 (IRS4) and collagen, type IV, alpha 5 (COL4A5), the expressions of which were analysed by the use of RQ-PCR.
  • [MeSH-major] Chromosomes, Human, Pair 7 / genetics. Chromosomes, Human, X / genetics. Insulin Receptor Substrate Proteins / genetics. Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / genetics. Translocation, Genetic

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19055661.001).
  • [ISSN] 1365-2141
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Insulin Receptor Substrate Proteins; 0 / Receptors, Antigen, T-Cell, alpha-beta
  •  go-up   go-down


53. Dai L, Gast A, Horska A, Schrappe M, Bartram CR, Hemminki K, Kumar R, Bermejo JL: A case-control study of childhood acute lymphoblastic leukaemia and polymorphisms in the TGF-beta and receptor genes. Pediatr Blood Cancer; 2009 Jul;52(7):819-23
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case-control study of childhood acute lymphoblastic leukaemia and polymorphisms in the TGF-beta and receptor genes.
  • BACKGROUND: Inherited genetic variants in critical genes can putatively modulate susceptibility to childhood acute lymphoblastic leukemia (ALL).
  • METHODS: We used allelic discrimination method to genotype 19 polymorphisms in the transforming growth factor-beta1 (TGF-beta1), transforming growth factor-beta receptor 1 (TGF-betaR1) and transforming growth factor-beta receptor 2 (TGF-betaR2) genes in 460 cases of childhood acute ALL and 552 ethnically matched controls.
  • [MeSH-major] Polymorphism, Single Nucleotide / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Protein-Serine-Threonine Kinases / genetics. Receptors, Transforming Growth Factor beta / genetics. Transforming Growth Factor beta / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2009 Wiley-Liss, Inc.
  • (PMID = 19229971.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Receptors, Transforming Growth Factor beta; 0 / Transforming Growth Factor beta; EC 2.7.1.11 / TGF-beta type I receptor; EC 2.7.11.1 / Protein-Serine-Threonine Kinases; EC 2.7.11.30 / transforming growth factor-beta type II receptor
  •  go-up   go-down


54. Beesley AH, Rampellini JL, Palmer ML, Heng JY, Samuels AL, Firth MJ, Ford J, Kees UR: Influence of wild-type MLL on glucocorticoid sensitivity and response to DNA-damage in pediatric acute lymphoblastic leukemia. Mol Cancer; 2010;9:284
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Influence of wild-type MLL on glucocorticoid sensitivity and response to DNA-damage in pediatric acute lymphoblastic leukemia.
  • BACKGROUND: Rearrangement of the mixed-lineage leukemia gene (MLL) is found in 80% of infant acute lymphoblastic leukemia (ALL) and is associated with poor prognosis and resistance to glucocorticoids (GCs).
  • The absence of MLL-rearrangements suggested that this relationship represented expression of wild-type MLL.
  • RNAi knockdown of MLL expression in T-ALL cell lines significantly increased resistance to dexamethasone and gamma irradiation indicating an important role for wild-type MLL in the control of cellular apoptosis.
  • CONCLUSIONS: The data suggests that reduced expression of wild-type MLL can contribute to GC resistance in ALL patients both with and without MLL-translocations.
  • [MeSH-major] DNA Damage / genetics. Drug Resistance, Neoplasm / genetics. Glucocorticoids / pharmacology. Lymphocytes / drug effects. Myeloid-Lymphoid Leukemia Protein / metabolism. Precursor Cell Lymphoblastic Leukemia-Lymphoma / metabolism

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • MedlinePlus Health Information. consumer health - Steroids.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Proc Natl Acad Sci U S A. 2003 Jun 24;100(13):7853-8 [12782787.001]
  • [Cites] Nature. 2010 Sep 16;467(7313):343-6 [20818375.001]
  • [Cites] Blood. 2003 Oct 15;102(8):2951-9 [12730115.001]
  • [Cites] Leukemia. 2004 Mar;18(3):521-9 [14712291.001]
  • [Cites] N Engl J Med. 2004 Aug 5;351(6):533-42 [15295046.001]
  • [Cites] Blood. 1995 Sep 1;86(5):1881-6 [7655016.001]
  • [Cites] Blood. 1995 Nov 15;86(10):3861-8 [7579354.001]
  • [Cites] J Clin Oncol. 1998 Apr;16(4):1270-8 [9552025.001]
  • [Cites] Leukemia. 1998 Sep;12(9):1344-8 [9737681.001]
  • [Cites] Blood. 1999 Jul 1;94(1):283-90 [10381524.001]
  • [Cites] Br J Haematol. 2005 Apr;129(2):189-98 [15813846.001]
  • [Cites] Semin Cancer Biol. 2005 Jun;15(3):175-88 [15826832.001]
  • [Cites] BMC Genomics. 2005;6:59 [15854232.001]
  • [Cites] Eur J Cancer. 2005 Jun;41(9):1300-3 [15869873.001]
  • [Cites] Blood. 2005 Jul 1;106(1):345-52 [15774615.001]
  • [Cites] J Biol Chem. 2005 Jul 1;280(26):24315-21 [15851483.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Oct 25;102(43):15545-50 [16199517.001]
  • [Cites] Oncogene. 1999 Dec 2;18(51):7387-8 [10602495.001]
  • [Cites] FASEB J. 2001 Mar;15(3):693-9 [11259387.001]
  • [Cites] Leukemia. 2002 May;16(5):949-51 [11986959.001]
  • [Cites] Leukemia. 2003 Apr;17(4):700-6 [12682627.001]
  • [Cites] Nat Genet. 2005 Nov;37(11):1289-95 [16200064.001]
  • [Cites] Br J Haematol. 2005 Nov;131(4):447-56 [16281934.001]
  • [Cites] Br J Haematol. 2006 Mar;132(5):539-51 [16445826.001]
  • [Cites] Blood. 2006 Mar 1;107(5):2061-9 [16293608.001]
  • [Cites] Leukemia. 2006 Jan;20(1):179-82 [16307022.001]
  • [Cites] Leukemia. 2006 May;20(5):777-84 [16511515.001]
  • [Cites] Cancer Res. 2006 May 1;66(9):4591-601 [16651409.001]
  • [Cites] Blood. 2006 Jun 15;107(12):4663-5 [16478880.001]
  • [Cites] Genes Chromosomes Cancer. 2006 Aug;45(8):754-60 [16688745.001]
  • [Cites] Blood. 2006 Jul 15;108(2):441-51 [16556894.001]
  • [Cites] Br J Cancer. 2006 Dec 4;95(11):1537-44 [17117183.001]
  • [Cites] Br J Haematol. 2007 Apr;137(2):109-16 [17391490.001]
  • [Cites] Genes Dev. 2007 Oct 1;21(19):2385-98 [17908926.001]
  • [Cites] Leuk Lymphoma. 2007 Oct;48(10):2083-6 [17917979.001]
  • [Cites] Nat Rev Cancer. 2007 Nov;7(11):823-33 [17957188.001]
  • [Cites] Int J Hematol. 2008 Jan;87(1):10-8 [18224408.001]
  • [Cites] Br J Haematol. 2008 Mar;140(6):716-9 [18218047.001]
  • [Cites] Leuk Res. 2009 Feb;33(2):321-5 [18789525.001]
  • [Cites] Apoptosis. 2009 Jun;14(6):821-8 [19421859.001]
  • [Cites] Science. 2009 May 22;324(5930):1029-33 [19460998.001]
  • [Cites] BMC Cancer. 2009;9:147 [19445675.001]
  • [Cites] Br J Cancer. 2009 Jun 16;100(12):1926-36 [19436302.001]
  • [Cites] EMBO J. 2009 Oct 21;28(20):3185-95 [19763085.001]
  • [Cites] Blood. 2009 Nov 5;114(19):4169-78 [19749093.001]
  • [Cites] Cancer Res. 2003 Aug 15;63(16):4882-7 [12941810.001]
  • (PMID = 20979663.001).
  • [ISSN] 1476-4598
  • [Journal-full-title] Molecular cancer
  • [ISO-abbreviation] Mol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Glucocorticoids; 149025-06-9 / Myeloid-Lymphoid Leukemia Protein
  • [Other-IDs] NLM/ PMC2987983
  •  go-up   go-down


55. Bercovich D, Ganmore I, Scott LM, Wainreb G, Birger Y, Elimelech A, Shochat C, Cazzaniga G, Biondi A, Basso G, Cario G, Schrappe M, Stanulla M, Strehl S, Haas OA, Mann G, Binder V, Borkhardt A, Kempski H, Trka J, Bielorei B, Avigad S, Stark B, Smith O, Dastugue N, Bourquin JP, Tal NB, Green AR, Izraeli S: Mutations of JAK2 in acute lymphoblastic leukaemias associated with Down's syndrome. Lancet; 2008 Oct 25;372(9648):1484-92
SciCrunch. OMIM: Data: Gene Annotation .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mutations of JAK2 in acute lymphoblastic leukaemias associated with Down's syndrome.
  • BACKGROUND: Children with Down's syndrome have a greatly increased risk of acute megakaryoblastic and acute lymphoblastic leukaemias.
  • Acute megakaryoblastic leukaemia in Down's syndrome is characterised by a somatic mutation in GATA1.
  • We tested the hypothesis that mutations in JAK2 might be a common molecular event in acute lymphoblastic leukaemia associated with Down's syndrome.
  • METHODS: JAK2 DNA mutational analysis was done on diagnostic bone marrow samples obtained from 88 patients with Down's syndrome-associated acute lymphoblastic leukaemia; and 216 patients with sporadic acute lymphoblastic leukaemia, Down's syndrome-associated acute megakaryoblastic leukaemia, and essential thrombocythaemia.
  • FINDINGS: Somatically acquired JAK2 mutations were identified in 16 (18%) patients with Down's syndrome-associated acute lymphoblastic leukaemia.
  • The only patient with non-Down's syndrome-associated leukaemia but with a JAK2 mutation had an isochromosome 21q.
  • INTERPRETATION: A specific genotype-phenotype association exists between the type of somatic mutation within the JAK2 pseudokinase domain and the development of B-lymphoid or myeloid neoplasms.
  • Somatically acquired R683 JAK2 mutations define a distinct acute lymphoblastic leukaemia subgroup that is uniquely associated with trisomy 21.
  • JAK2 inhibitors could be useful for treatment of this leukaemia.
  • [MeSH-major] Down Syndrome / complications. Down Syndrome / genetics. GATA1 Transcription Factor / genetics. Janus Kinase 2 / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics


56. Uckun F, Ozer Z, Vassilev A: Bruton's tyrosine kinase prevents activation of the anti-apoptotic transcription factor STAT3 and promotes apoptosis in neoplastic B-cells and B-cell precursors exposed to oxidative stress. Br J Haematol; 2007 Feb;136(4):574-89
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Defective BTK expression in leukaemic B-cell precursors from infants with t(4;11) acute lymphoblastic leukaemia has been associated with radiation resistance.
  • Reconstitution of BTK-deficient DT40 cells with wild-type human BTK gene eliminated the amplification of the STAT3 response and restored the PV-induced apoptotic signal.
  • Similarly, while the BTK-positive NALM-6 human leukaemic B-cell precursor cell line showed no STAT3 activation after PV treatment and was exquisitely sensitive to PV-induced apoptosis, PV failed to induce apoptosis in BTK-deficient RAMOS-1 human lymphoma B-cells that showed a robust STAT3 response.
  • [MeSH-major] Leukemia, B-Cell / pathology. Lymphoma, B-Cell / pathology. Neoplasm Proteins / metabolism. Protein-Tyrosine Kinases / physiology. STAT3 Transcription Factor / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17367410.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Enzyme Inhibitors; 0 / Neoplasm Proteins; 0 / Recombinant Proteins; 0 / STAT3 Transcription Factor; 0 / pervanadate; 3WHH0066W5 / Vanadates; EC 2.7.10.1 / Agammaglobulinaemia tyrosine kinase; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 3.1.3.48 / Protein Tyrosine Phosphatases
  •  go-up   go-down


57. Eyada TK, El Ghonemy EG, El Ghoroury EA, El Bassyouni SO, El Masry MK: Study of genetic polymorphism of xenobiotic enzymes in acute leukemia. Blood Coagul Fibrinolysis; 2007 Jul;18(5):489-95
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Study of genetic polymorphism of xenobiotic enzymes in acute leukemia.
  • The work studied possible association between genetic polymorphisms of CYP2D6, GSTM1, GSTT1and NQO1 and altered susceptibility to leukaemia, correlating these genetic polymorphisms with clinical prognostic data, response to therapy and relapse.
  • The study included 32 leukaemia patients, 19 with acute myeloid leukemia (AML) and 13 with acute lymphoid leukaemia (ALL), and 11 normal individuals (control group).
  • Results demonstrate a significant increase in the frequency of CYP2D6 wild-type and GSTM1 null genotypes in the acute leukaemia group compared with the control.
  • Studying the relationship between polymorphisms of these genes and the outcome of our cases revealed the wild genotype of CYP2D6 significantly influenced the outcome of acute leukaemia particularly in AML cases, while GSTM1 null genotype was associated with bad prognosis among the ALL group.
  • The study also revealed that patients with combined mutant CYP2D6/present GSTM1/present GSTT1 achieved the best prognosis, suggesting synergistic impact of these genetic polymorphisms on the outcome of acute leukaemia cases.
  • This case-control study suggests a contribution of CYP2D6 and GSTM1 null variants in the development of acute leukaemia.
  • [MeSH-major] Cytochrome P-450 CYP2D6 / genetics. Glutathione Transferase / genetics. Leukemia, Myeloid, Acute / genetics. NAD(P)H Dehydrogenase (Quinone) / genetics. Polymorphism, Genetic. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17581325.001).
  • [ISSN] 0957-5235
  • [Journal-full-title] Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis
  • [ISO-abbreviation] Blood Coagul. Fibrinolysis
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] EC 1.14.14.1 / Cytochrome P-450 CYP2D6; EC 1.6.5.2 / NAD(P)H Dehydrogenase (Quinone); EC 1.6.5.2 / NQO1 protein, human; EC 2.5.1.- / glutathione S-transferase T1; EC 2.5.1.18 / Glutathione Transferase; EC 2.5.1.18 / glutathione S-transferase M1
  •  go-up   go-down


58. Gauffin F, Diffner E, Gustafsson B, Nordgren A, Wingren AG, Sander B, Persson JL, Gustafsson B: Expression of PTEN and SHP1, investigated from tissue microarrays in pediatric acute lymphoblastic, leukemia. Pediatr Hematol Oncol; 2009 Jan;26(1):48-56
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of PTEN and SHP1, investigated from tissue microarrays in pediatric acute lymphoblastic, leukemia.
  • The authors investigated the protein expression of PTEN and SHP1, by immunohistochemistry in tissue microarrays from bone marrow samples in children, diagnosed with acute lymphoblastic leukaemia and nonmalignant controls.
  • The roles of PTEN and SHP1 are not well investigated in pediatric leukemia and could in the future play a role as prognostic factors.
  • [MeSH-major] PTEN Phosphohydrolase / analysis. Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology. Protein Tyrosine Phosphatase, Non-Receptor Type 6 / analysis

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19206008.001).
  • [ISSN] 1521-0669
  • [Journal-full-title] Pediatric hematology and oncology
  • [ISO-abbreviation] Pediatr Hematol Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 3.1.3.48 / PTEN protein, human; EC 3.1.3.48 / PTPN6 protein, human; EC 3.1.3.48 / Protein Tyrosine Phosphatase, Non-Receptor Type 6; EC 3.1.3.67 / PTEN Phosphohydrolase
  •  go-up   go-down


59. Harrison CJ, Griffiths M, Moorman F, Schnittger S, Cayuela JM, Shurtleff S, Gottardi E, Mitterbauer G, Colomer D, Delabesse E, Castéras V, Maroc N: A multicenter evaluation of comprehensive analysis of MLL translocations and fusion gene partners in acute leukemia using the MLL FusionChip device. Cancer Genet Cytogenet; 2007 Feb;173(1):17-22
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A multicenter evaluation of comprehensive analysis of MLL translocations and fusion gene partners in acute leukemia using the MLL FusionChip device.
  • Rearrangements of the MLL gene are significant in acute leukemia.
  • Among the most frequent translocations are t(4;11)(q21;q23) and t(9;11)(p22;q23), which give rise to the MLL-AFF1 and MLL-MLLT3 fusion genes (alias MLL-AF4 and MLL-AF9) in acute lymphoblastic and acute myeloid leukemia, respectively.
  • Current evidence suggests that determining the MLL status of acute leukemia, including precise identification of the partner gene, is important in defining appropriate treatment.
  • A novel molecular diagnostic device, the MLL FusionChip, has been successfully used to identify MLL fusion gene translocations in acute leukemia, including the precise breakpoint location.
  • The type of molecular information provided by MLL FusionChip gave an indication of the appropriate primers to design for disease monitoring of MLL patients following treatment.
  • [MeSH-major] Leukemia, Myeloid / genetics. Myeloid-Lymphoid Leukemia Protein / genetics. Oncogene Proteins, Fusion / genetics. Translocation, Genetic
  • [MeSH-minor] Acute Disease. Adult. Child. Chromosomes, Human, Pair 11. Chromosomes, Human, Pair 4. Chromosomes, Human, Pair 9. Histone-Lysine N-Methyltransferase. Humans. In Situ Hybridization, Fluorescence. Infant. Oligonucleotide Array Sequence Analysis / instrumentation. Oligonucleotide Array Sequence Analysis / methods. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology. RNA, Neoplasm / genetics. RNA, Neoplasm / metabolism. Reverse Transcriptase Polymerase Chain Reaction

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Cancer Genet Cytogenet. 2007 Dec;179(2):167
  • (PMID = 17284365.001).
  • [ISSN] 0165-4608
  • [Journal-full-title] Cancer genetics and cytogenetics
  • [ISO-abbreviation] Cancer Genet. Cytogenet.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / MLL protein, human; 0 / MLL-AF4 fusion protein, human; 0 / MLL-AF9 fusion protein, human; 0 / Oncogene Proteins, Fusion; 0 / RNA, Neoplasm; 149025-06-9 / Myeloid-Lymphoid Leukemia Protein; EC 2.1.1.43 / Histone-Lysine N-Methyltransferase
  •  go-up   go-down


60. Kroczka S, Steczkowska-Klucznik M, Romaniszyn A: [Auditory evoked potentials in patients after acute children's lymphoblastic leukemia treatment]. Przegl Lek; 2006;63(11):1205-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Auditory evoked potentials in patients after acute children's lymphoblastic leukemia treatment].
  • BACKGROUND: Acute lymphoblastic leukaemia (ALL), and especially its treatment often leads to irreversible consequences in the central and peripheral nervous system.
  • The issue of analysis was the influence of past ALL and type of therapy on parameters of egzogenic potentials triggered by acoustic stimulus (BAEP) in patients after termination of treatment.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Evoked Potentials, Auditory, Brain Stem / drug effects. Hearing Disorders / chemically induced. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • MedlinePlus Health Information. consumer health - Hearing Disorders and Deafness.
  • MedlinePlus Health Information. consumer health - Hearing Problems in Children.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. THIOGUANINE .
  • Hazardous Substances Data Bank. DAUNORUBICIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. MERCAPTOPURINE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17348417.001).
  • [ISSN] 0033-2240
  • [Journal-full-title] Przegla̧d lekarski
  • [ISO-abbreviation] Prz. Lek.
  • [Language] pol
  • [Publication-type] Clinical Trial; English Abstract; Journal Article
  • [Publication-country] Poland
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; E7WED276I5 / 6-Mercaptopurine; EC 3.5.1.1 / Asparaginase; FTK8U1GZNX / Thioguanine; VB0R961HZT / Prednisone; YL5FZ2Y5U1 / Methotrexate; ZS7284E0ZP / Daunorubicin; BFM 78 protocol; BFM-86 protocol; New York protocol
  •  go-up   go-down


61. Pop-Jora D, Berhoune C, Najioullah F, Girard S, Mialou V, Bleyzac N, Galambrun C, Bertrand Y: [Human herpesvirus 6 encephalitis after bone marrow transplantation]. Arch Pediatr; 2006 Dec;13(12):1518-20
Hazardous Substances Data Bank. GANCICLOVIR .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Un cas d'encéphalite à herpès virus humain de type 6 après transplantation de moelle osseuse.
  • We report on a 7-year-old boy with relapsed acute lymphoblastic leukaemia, who developed HHV-6 encephalitis after bone marrow transplantation; the patient recovered after treatment with ganciclovir.
  • [MeSH-minor] Antiviral Agents / administration & dosage. Antiviral Agents / therapeutic use. Child. Follow-Up Studies. Ganciclovir / administration & dosage. Ganciclovir / therapeutic use. Graft vs Host Disease / complications. Humans. Male. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy. Recurrence. Time Factors. Treatment Outcome

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Bone Marrow Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17092696.001).
  • [ISSN] 0929-693X
  • [Journal-full-title] Archives de pédiatrie : organe officiel de la Sociéte française de pédiatrie
  • [ISO-abbreviation] Arch Pediatr
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antiviral Agents; P9G3CKZ4P5 / Ganciclovir
  •  go-up   go-down


62. Mansour MR, Sulis ML, Duke V, Foroni L, Jenkinson S, Koo K, Allen CG, Gale RE, Buck G, Richards S, Paietta E, Rowe JM, Tallman MS, Goldstone AH, Ferrando AA, Linch DC: Prognostic implications of NOTCH1 and FBXW7 mutations in adults with T-cell acute lymphoblastic leukemia treated on the MRC UKALLXII/ECOG E2993 protocol. J Clin Oncol; 2009 Sep 10;27(26):4352-6
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic implications of NOTCH1 and FBXW7 mutations in adults with T-cell acute lymphoblastic leukemia treated on the MRC UKALLXII/ECOG E2993 protocol.
  • PURPOSE: Notch pathway activation by mutations in either NOTCH1 and/or FBXW7 is one of the most common molecular events in T-cell acute lymphoblastic leukemia (T-ALL) and, in pediatric disease, predicts for favorable outcome.
  • We sought to evaluate the outcome according to mutation status of patients with adult T-ALL treated on the United Kingdom Acute Lymphoblastic Leukaemia XII (UKALLXII)/Eastern Cooperative Oncology Group (ECOG) E2993 protocol.
  • Patients wild type (WT) for both markers trended toward poorer event-free survival (EFS; MUT v WT, 51% v 27%, P = .10; hazard ratio, 0.6).
  • [MeSH-major] Cell Cycle Proteins / genetics. F-Box Proteins / genetics. Mutation. Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / therapy. Receptor, Notch1 / genetics. Ubiquitin-Protein Ligases / genetics

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2006 Feb 1;107(3):1116-23 [16195338.001]
  • [Cites] Blood. 2005 Dec 1;106(12):3760-7 [16105981.001]
  • [Cites] Clin Cancer Res. 2006 May 15;12(10):3043-9 [16707600.001]
  • [Cites] Genes Dev. 2006 Aug 1;20(15):2096-109 [16847353.001]
  • [Cites] Blood. 2006 Aug 15;108(4):1151-7 [16614245.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Nov 28;103(48):18261-6 [17114293.001]
  • [Cites] Nat Med. 2007 Jan;13(1):70-7 [17173050.001]
  • [Cites] Blood. 2007 Feb 1;109(3):910-5 [17023577.001]
  • [Cites] Blood. 2007 Apr 15;109(8):3189-97 [17170120.001]
  • [Cites] Cancer Res. 2007 Jun 15;67(12):5611-6 [17575125.001]
  • [Cites] Blood. 2007 Jul 1;110(1):278-86 [17363738.001]
  • [Cites] Nature. 2007 Jun 21;447(7147):966-71 [17515920.001]
  • [Cites] Blood. 2007 Aug 15;110(4):1262-70 [17456725.001]
  • [Cites] J Exp Med. 2007 Aug 6;204(8):1825-35 [17646408.001]
  • [Cites] J Exp Med. 2007 Aug 6;204(8):1813-24 [17646409.001]
  • [Cites] Nat Med. 2007 Oct;13(10):1203-10 [17873882.001]
  • [Cites] Clin Cancer Res. 2007 Dec 1;13(23):6964-9 [18056171.001]
  • [Cites] Blood. 2008 Feb 15;111(4):1827-33 [18048644.001]
  • [Cites] Leuk Res. 2008 Nov;32(11):1751-5 [18485478.001]
  • [Cites] Blood. 2008 Aug 1;112(3):733-40 [18411416.001]
  • [Cites] Blood. 2009 Apr 23;113(17):3918-24 [19109228.001]
  • [Cites] Blood. 2002 Jun 15;99(12):4386-93 [12036866.001]
  • [Cites] Haematologica. 2002 Nov;87(11):1126-34 [12414341.001]
  • [Cites] Leukemia. 2003 Nov;17(11):2149-56 [14576730.001]
  • [Cites] Lancet. 2004 Feb 14;363(9408):535-6 [14975618.001]
  • [Cites] Science. 2004 Oct 8;306(5694):269-71 [15472075.001]
  • [Cites] Blood. 1988 Jan;71(1):123-31 [3422030.001]
  • [Cites] Leukemia. 1998 Apr;12(4):463-73 [9557602.001]
  • [Cites] Leukemia. 2006 Mar;20(3):537-9 [16424867.001]
  • (PMID = 19635999.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Databank-accession-numbers] ClinicalTrials.gov/ NCT00002514
  • [Grant] United States / NCI NIH HHS / CA / R01 CA129382; United Kingdom / Medical Research Council / / ; United Kingdom / Medical Research Council / / MRC/ MC/ U137686856; United States / NCI NIH HHS / CA / R01CA120196; United States / NCI NIH HHS / CA / R01CA129382; United Kingdom / Medical Research Council / / MRC/ G0500389; United States / NCI NIH HHS / CA / R01 CA120196; United States / NCI NIH HHS / CA / U24 CA114737; United States / NCI NIH HHS / CA / R01 CA120196-03
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cell Cycle Proteins; 0 / F-Box Proteins; 0 / NOTCH1 protein, human; 0 / Receptor, Notch1; EC 2.3.2.27 / Ubiquitin-Protein Ligases; EC 6.3.2.19 / FBXW7 protein, human
  • [Other-IDs] NLM/ PMC2744275
  •  go-up   go-down


63. Oshimi K: Progress in understanding and managing natural killer-cell malignancies. Br J Haematol; 2007 Nov;139(4):532-44
MedlinePlus Health Information. consumer health - Chronic Lymphocytic Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The World Health Organization classification of haematolymphoid tumours recognizes three categories of natural killer (NK)-cell neoplasms: blastic NK-cell lymphoma, aggressive NK-cell leukaemia, and extranodal NK/T-cell lymphoma, nasal-type.
  • Recent studies indicate that CD4+CD56+ blastic NK-cell lymphoma is of plasmacytoid dendritic cell origin, and true tumours of precursor NK-cell origin may be present mainly in the CD4-CD56+ subset.
  • Myeloid/NK-cell precursor acute leukaemia may also develop from precursor NK cells.
  • However, because the developmental pathway of normal NK cells is not well understood, tumours of precursor NK-cell origin are not clearly identified.
  • Aggressive NK-cell leukaemia is rare and has a poor prognosis.
  • [MeSH-major] Killer Cells, Natural / pathology. Leukemia, Lymphoid / therapy
  • [MeSH-minor] Acute Disease. Cell Lineage. Cell Transformation, Neoplastic / pathology. Chronic Disease. Humans. Neoplasm Staging. Preleukemia / pathology. Prognosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17916099.001).
  • [ISSN] 1365-2141
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Number-of-references] 132
  •  go-up   go-down


64. Muszyńska-Rosłan K, Krawczuk-Rybak M, Protas P, Siedlecka E, Wiśniewska M, Wołczyński S: [Biochemical markers of bone formation activity in children with neoplasms]. Wiad Lek; 2005;58(1-2):29-35
MedlinePlus Health Information. consumer health - Cancer in Children.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We explored the relationships between sex, pubertal development and type of neoplastic disease.
  • 85 children (53 boys) with newly diagnosed neoplasms: 48 with acute lymphoblastic leukaemia (ALL), 13 with Hodgkin's disease and 22 with solid tumors (group I) and 111 healthy children (group II) were studied.
  • ICTP (cross-linked telopeptide of type 1 collagen), 4. parathormon (PTH), as the markers of bone resorption. RESULTS: 1.
  • The values of ICTP did not depend on the type of disease, sex and pubertal stage, except the children before puberty.
  • This correlation was observed in children with leukaemia (r = 0.55, p < 0.05), especially in girls (r = 0.9, p < 0.05).
  • [MeSH-minor] Adolescent. Alkaline Phosphatase / blood. Case-Control Studies. Child. Collagen Type I. Female. Humans. Male. Osteocalcin / blood. Parathyroid Hormone / blood. Peptide Fragments / blood. Peptides. Precursor Cell Lymphoblastic Leukemia-Lymphoma / blood. Procollagen / blood

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15991550.001).
  • [ISSN] 0043-5147
  • [Journal-full-title] Wiadomości lekarskie (Warsaw, Poland : 1960)
  • [ISO-abbreviation] Wiad. Lek.
  • [Language] pol
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Collagen Type I; 0 / Parathyroid Hormone; 0 / Peptide Fragments; 0 / Peptides; 0 / Procollagen; 0 / collagen type I trimeric cross-linked peptide; 104982-03-8 / Osteocalcin; EC 3.1.3.1 / Alkaline Phosphatase
  •  go-up   go-down


65. Bonifaz A, Macias B, Paredes-Farrera F, Arias P, Ponce RM, Araiza J: Palatal zygomycosis: experience of 21 cases. Oral Dis; 2008 Sep;14(6):569-74
Hazardous Substances Data Bank. FLUCONAZOLE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The associated pre-disposing factors were: ketoacidotic diabetes (five type-1 and 15 type-2), and acute leukaemia in one patient.
  • CONCLUSION: Zygomycosis with palatal involvement occurs in around 18% of cases, usually associated with RC modalities; it has an acute and generally lethal course.
  • [MeSH-minor] Absidia / isolation & purification. Adolescent. Adult. Aged. Amphotericin B / administration & dosage. Amphotericin B / therapeutic use. Antifungal Agents / administration & dosage. Antifungal Agents / therapeutic use. Brain Diseases / microbiology. Child. Diabetic Ketoacidosis / complications. Drug Combinations. Female. Fluconazole / administration & dosage. Fluconazole / therapeutic use. Humans. Itraconazole / administration & dosage. Itraconazole / therapeutic use. Male. Mucormycosis / diagnosis. Mucormycosis / drug therapy. Nose Diseases / microbiology. Opportunistic Infections / diagnosis. Oral Ulcer / microbiology. Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / complications. Retrospective Studies. Rhizopus / isolation & purification. Treatment Outcome


66. Zidar N, Gale N, Zupevc A, Zargi M: Salivary gland tumours as second neoplasms: two cases and literature review. J Laryngol Otol; 2010 May;124(5):577-80
MedlinePlus Health Information. consumer health - Salivary Gland Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Mucoepidermoid carcinoma of the parotid gland is by far the most common type of second salivary gland tumour; other types have rarely been reported.
  • CASE REPORTS: The first patient was a 22-year-old woman with a low grade mucoepidermoid carcinoma of the parotid gland, which developed 21 years after completion of chemoradiotherapy for acute lymphoblastic leukaemia.
  • [MeSH-minor] Adult. Female. Humans. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19922704.001).
  • [ISSN] 1748-5460
  • [Journal-full-title] The Journal of laryngology and otology
  • [ISO-abbreviation] J Laryngol Otol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 31
  •  go-up   go-down


67. Bryant J, Picot J, Levitt G, Sullivan I, Baxter L, Clegg A: Cardioprotection against the toxic effects of anthracyclines given to children with cancer: a systematic review. Health Technol Assess; 2007 Jul;11(27):iii, ix-x, 1-84
PubMed Health. PubMed Health .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: Four randomised controlled trials (RCTs) met the inclusion criteria of the review, each considering a different cardioprotective intervention; all trials included children with acute lymphoblastic leukaemia, and one also included children with non-Hodgkin's lymphoma.
  • Two cohort studies considering atrial natriuretic peptide and two considering brain (B-type) natriuretic peptide suggested that these chemicals are elevated in some subgroups of children treated with anthracyclines for cancer.
  • N-terminal B-type natriuretic peptide levels were significantly elevated in children treated with anthracyclines who had cardiac dysfunction.
  • [MeSH-major] Anthracyclines / adverse effects. Anthracyclines / economics. Antibiotics, Antineoplastic / adverse effects. Antibiotics, Antineoplastic / economics. Cardiovascular Agents / therapeutic use. Heart Diseases / prevention & control. Lymphoma, Non-Hodgkin / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy

  • MedlinePlus Health Information. consumer health - Heart Diseases.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17610809.001).
  • [ISSN] 1366-5278
  • [Journal-full-title] Health technology assessment (Winchester, England)
  • [ISO-abbreviation] Health Technol Assess
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anthracyclines; 0 / Antibiotics, Antineoplastic; 0 / Biomarkers; 0 / Cardiovascular Agents
  • [Number-of-references] 44
  •  go-up   go-down


68. Erdilyi DJ, Kámory E, Csókay B, Andrikovics H, Tordai A, Kiss C, Filni-Semsei A, Janszky I, Zalka A, Fekete G, Falus A, Kovács GT, Szalai C: Synergistic interaction of ABCB1 and ABCG2 polymorphisms predicts the prevalence of toxic encephalopathy during anticancer chemotherapy. Pharmacogenomics J; 2008 Oct;8(5):321-7
Pharmacogenomics Knowledge Base. meta-databases - Pharmacogenomic Annotation 827854337 for PMID:17938643 [PharmGKB] .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Data from 291 children with acute lymphoblastic leukaemia were analysed in this retrospective study.
  • Patients with the ABCG2 421A allele tended to have more complications than wild type homozygotes (OR=2.0; P=0.25).
  • [MeSH-major] ATP-Binding Cassette Transporters / genetics. Antineoplastic Agents / adverse effects. Epistasis, Genetic. Neoplasm Proteins / genetics. Neurotoxicity Syndromes / etiology. P-Glycoprotein / genetics. Polymorphism, Genetic. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17938643.001).
  • [ISSN] 1473-1150
  • [Journal-full-title] The pharmacogenomics journal
  • [ISO-abbreviation] Pharmacogenomics J.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / ABCB1 protein, human; 0 / ABCG2 protein, human; 0 / Antineoplastic Agents; 0 / Neoplasm Proteins; 0 / P-Glycoprotein; 0 / P-Glycoproteins
  •  go-up   go-down


69. Vanmassenhove J, Sallée M, Guilpain P, Vanholder R, De Potter A, Libbrecht L, Suarez F, Hermine O, Fakhouri F: Fanconi syndrome in lymphoma patients: report of the first case series. Nephrol Dial Transplant; 2010 Aug;25(8):2516-20
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In six patients, the lymphoma was of the acute T cell leukaemia/lymphoma (ATLL) type, related to human T cell lymphotropic virus 1 (HTLV1) infection.
  • [MeSH-major] Fanconi Syndrome / epidemiology. Lymphoma / epidemiology. Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / epidemiology

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20154363.001).
  • [ISSN] 1460-2385
  • [Journal-full-title] Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association
  • [ISO-abbreviation] Nephrol. Dial. Transplant.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


70. van Dalen EC, Raphaël MF, Caron HN, Kremer LC: Treatment including anthracyclines versus treatment not including anthracyclines for childhood cancer. Cochrane Database Syst Rev; 2009;(1):CD006647
MedlinePlus Health Information. consumer health - Cancer in Children.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • SELECTION CRITERIA: Randomised controlled trials (RCTs) comparing treatment of any type of childhood cancer with and without anthracyclines and reporting outcomes concerning antitumour efficacy.
  • MAIN RESULTS: We identified RCTs for 5 types of tumour: acute lymphoblastic leukaemia (ALL) (n=3; 912 children), Wilms' tumour (n=1; 316 children), rhabdomyosarcoma/undifferentiated sarcoma (n=1; 413 children), Ewing's sarcoma (n=1; 94 children), and non-Hodgkin lymphoma (n=1; 284 children).
  • [MeSH-minor] Bone Neoplasms / drug therapy. Child. Heart Diseases / chemically induced. Humans. Kidney Neoplasms / drug therapy. Lymphoma, Non-Hodgkin / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Randomized Controlled Trials as Topic. Sarcoma / drug therapy. Wilms Tumor / drug therapy

  • Genetic Alliance. consumer health - Childhood Cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [UpdateIn] Cochrane Database Syst Rev. 2011;(1):CD006647 [21249679.001]
  • (PMID = 19160293.001).
  • [ISSN] 1469-493X
  • [Journal-full-title] The Cochrane database of systematic reviews
  • [ISO-abbreviation] Cochrane Database Syst Rev
  • [Language] eng
  • [Publication-type] Journal Article; Meta-Analysis; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anthracyclines; 0 / Antibiotics, Antineoplastic
  • [Number-of-references] 172
  •  go-up   go-down


71. Navid F, Billups C, Liu T, Krasin MJ, Rodriguez-Galindo C: Second cancers in patients with the Ewing sarcoma family of tumours. Eur J Cancer; 2008 May;44(7):983-91
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Cumulative incidence (CI) of SM by the type of malignancy and treatment was estimated.
  • Secondary leukaemia (SL) developed in 8 patients (2 ALL, 6 MDS/AML), a median 2.6 years (range 1.4-19.6 years) after diagnosis of ESFT.

  • Genetic Alliance. consumer health - Ewing's Sarcoma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Pediatr Hematol Oncol. 2000 Jul-Aug;22(4):321-9 [10959902.001]
  • [Cites] N Engl J Med. 1987 Sep 3;317(10):588-93 [3475572.001]
  • [Cites] Clin Radiol. 2001 Jan;56(1):22-9 [11162693.001]
  • [Cites] J Clin Oncol. 2001 Apr 15;19(8):2134-41 [11304765.001]
  • [Cites] Med Pediatr Oncol. 2001 May;36(5):525-35 [11340607.001]
  • [Cites] Leuk Lymphoma. 2000 Nov;39(5-6):465-75 [11342330.001]
  • [Cites] Ann Oncol. 2001 Nov;12(11):1619-30 [11822764.001]
  • [Cites] Genes Chromosomes Cancer. 2002 Apr;33(4):331-45 [11921269.001]
  • [Cites] Blood. 2002 Jul 15;100(2):427-34 [12091332.001]
  • [Cites] Eur J Cancer. 2002 Nov;38(17):2243-51 [12441260.001]
  • [Cites] N Engl J Med. 2003 Feb 20;348(8):694-701 [12594313.001]
  • [Cites] J Clin Oncol. 2003 Apr 1;21(7):1195-204 [12663705.001]
  • [Cites] Am J Hematol. 2003 May;73(1):33-6 [12701117.001]
  • [Cites] Blood. 2003 May 15;101(10):3862-7 [12531808.001]
  • [Cites] Bone Marrow Transplant. 2003 Jul;32(1):31-4 [12815475.001]
  • [Cites] Exp Hematol. 2004 Jan;32(1):122-30 [14725909.001]
  • [Cites] Int J Cancer. 2004 May 20;110(1):87-93 [15054872.001]
  • [Cites] Br J Cancer. 1977 Jan;35(1):1-39 [831755.001]
  • [Cites] J Natl Cancer Inst. 1979 Jun;62(6):1401-6 [220452.001]
  • [Cites] Blood. 1981 Oct;58(4):759-67 [7272506.001]
  • [Cites] J Clin Oncol. 1983 Jan;1(1):45-51 [6668483.001]
  • [Cites] J Clin Oncol. 1986 Mar;4(3):325-45 [3950675.001]
  • [Cites] J Clin Oncol. 1986 Dec;4(12):1748-57 [3783201.001]
  • [Cites] J Clin Oncol. 1999 Jan;17(1):180-90 [10458232.001]
  • [Cites] J Clin Oncol. 1987 Nov;5(11):1822-6 [3316515.001]
  • [Cites] IARC Sci Publ. 1987;(82):1-406 [3329634.001]
  • [Cites] N Engl J Med. 1989 Jul 20;321(3):136-42 [2787477.001]
  • [Cites] Br J Haematol. 1990 Jul;75(3):442-4 [2248673.001]
  • [Cites] Blood. 1991 Aug 15;78(4):1147-8 [1651134.001]
  • [Cites] J Clin Oncol. 1992 Jan;10(1):156-63 [1309379.001]
  • [Cites] Clin Orthop Relat Res. 1992 Jan;(274):275-81 [1729013.001]
  • [Cites] J Clin Oncol. 1992 Nov;10(11):1737-42 [1403056.001]
  • [Cites] Med Pediatr Oncol. 1994;22(4):296-7 [8107665.001]
  • [Cites] Med Pediatr Oncol. 1994;23(5):406-12 [8084307.001]
  • [Cites] Leukemia. 1996 Mar;10(3):460-5 [8642862.001]
  • [Cites] J Clin Oncol. 1996 Oct;14(10):2818-25 [8874344.001]
  • [Cites] Med Pediatr Oncol. 1998 Apr;30(4):259-60 [9473762.001]
  • [Cites] J Clin Oncol. 1998 Sep;16(9):3016-20 [9738570.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1998 Sep 1;42(2):379-84 [9788419.001]
  • [Cites] Bone Marrow Transplant. 1999 Jan;23(1):21-5 [10037046.001]
  • [Cites] Bone Marrow Transplant. 1999 Oct;24(7):735-9 [10516676.001]
  • [Cites] Genes Chromosomes Cancer. 2005 Feb;42(2):107-16 [15543619.001]
  • [Cites] J Pediatr Hematol Oncol. 2005 Oct;27(10):517-20 [16217253.001]
  • [Cites] Bone Marrow Transplant. 2006 Jan;37(2):183-9 [16299545.001]
  • [Cites] Leukemia. 2006 Feb;20(2):239-46 [16341039.001]
  • [Cites] Cancer. 2006 Apr 15;106(8):1846-56 [16541446.001]
  • [Cites] N Engl J Med. 2006 May 11;354(19):2034-45 [16687716.001]
  • [Cites] Pediatr Blood Cancer. 2006 Dec;47(7):931-5 [16155933.001]
  • [Cites] Blood. 2007 Jan 1;109(1):46-51 [16985182.001]
  • [Cites] J Natl Cancer Inst. 2007 Feb 7;99(3):196-205 [17284714.001]
  • [Cites] Leuk Lymphoma. 2000 Mar;37(1-2):213-8 [10721789.001]
  • [Cites] J Pediatr Hematol Oncol. 1999 Nov-Dec;21(6):486-93 [10598659.001]
  • [Cites] J Clin Oncol. 2000 Sep;18(17):3108-14 [10963639.001]
  • (PMID = 18353632.001).
  • [ISSN] 0959-8049
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA23099; United States / NCI NIH HHS / CA / CA21765; United States / NCI NIH HHS / CA / P01 CA023099; United States / NCI NIH HHS / CA / P30 CA021765-29; United States / NCI NIH HHS / CA / P30 CA021765
  • [Publication-type] Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 143011-72-7 / Granulocyte Colony-Stimulating Factor
  • [Other-IDs] NLM/ NIHMS51653; NLM/ PMC2423466
  •  go-up   go-down


72. Roman E, Doyle P, Lightfoot T, Ansell P, Simpson J, Allan JM, Kinsey S, Eden TO: Molar pregnancy, childhood cancer and genomic imprinting - is there a link? Hum Fertil (Camb); 2006 Sep;9(3):171-4
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Nonetheless, whilst the associations were strongest for common precursor B-cell acute lymphoblastic leukaemia (OR 5.2, 95% CI 1.9 - 14.7) and sarcoma (OR 6.2, 95% CI 1.3 - 30.3), the spread across the remaining diagnostic groups suggests that the relationship, if confirmed, may be of a generalized, rather than specific, type.

  • Genetic Alliance. consumer health - Childhood Cancer.
  • Genetic Alliance. consumer health - Pregnancy.
  • MedlinePlus Health Information. consumer health - Cancer in Children.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17008269.001).
  • [ISSN] 1464-7273
  • [Journal-full-title] Human fertility (Cambridge, England)
  • [ISO-abbreviation] Hum Fertil (Camb)
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


73. Roti G, La Starza R, Ballanti S, Crescenzi B, Romoli S, Foá R, Tartaglia M, Aversa F, Fabrizio Martelli M, Mecucci C: Acute lymphoblastic leukaemia in Noonan syndrome. Br J Haematol; 2006 May;133(4):448-50
Genetic Alliance. consumer health - Noonan Syndrome.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acute lymphoblastic leukaemia in Noonan syndrome.
  • [MeSH-major] Noonan Syndrome / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics
  • [MeSH-minor] Adolescent. Germ-Line Mutation. Humans. Intracellular Signaling Peptides and Proteins / genetics. Male. Protein Tyrosine Phosphatase, Non-Receptor Type 11. Protein Tyrosine Phosphatases / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16643459.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Case Reports; Letter; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Intracellular Signaling Peptides and Proteins; EC 3.1.3.48 / PTPN11 protein, human; EC 3.1.3.48 / Protein Tyrosine Phosphatase, Non-Receptor Type 11; EC 3.1.3.48 / Protein Tyrosine Phosphatases
  •  go-up   go-down






Advertisement